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Abstract 
Raman spectroscopy is a growing technology in the fields of in-vitro drug and 
nanoparticle screening. The label free capability provided by vibrational 
spectroscopy, as well as the ability of the technique to probe the chemical nature 
of samples, makes it a good candidate for use in these fields. Crucial to the 
progress of these methods is the development and validation of robust and 
accurate multivariate statistical analysis protocols. In this thesis, both established 
and novel methods are examined using both real and simulated datasets. In 
particular, simulated datasets are used to validate and assess the accuracy of these 
methods in a spectroscopic setting. Firstly, partial least squares regression (PLSR) 
is examined using a simulated model based on real experimental data. This is 
applied to investigate the application of the algorithm to continuously varying 
data with known spectral perturbations introduced over a range of concentrations 
and responses. The results show that, while PLSR is valid for some dose ranges, 
sub-lethal, low concentrations and thus subtle spectral changes in the data may 
lead to difficulties in model construction. Multiple trends present in the data were 
also investigated and possible model error based on spectral bleedthrough in the 
regression coefficients RCs is explored. Principal component analysis (PCA) was 
also investigated using simulated datasets based on known changes in the data. 
Some of the limitations of PCA for data partitioning and trend analysis are 
overcome by a novel variant termed, ‘seeded’ PCA. 1st and 2nd derivative data is 
also explored for improvements in Raman spectral analysis using seeded PCA. 
Additionally, analytical methods used for Raman cellular imaging are also 
explored for nano applications, with two methods, classical least squares analysis 
 iii 
(CLSA) and a novel method spectral cross correlation analysis (SCCA) showing 
some improvements over current methodologies. Future work is also described 
pertaining to the use of a simulated cellular imaging dataset for validating data 
analysis protocols for spectral classification and in-vitro screening. 
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Figure 2.2 TERS probing hemozoin crystal formation inside malaria infected red 
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the tip following retraction from the cell, F SERS spectrum of β-hematin, G 
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Figure 2.3. Identification of intracellular distributions of polystyrene 
nanoparticles using Raman spectroscopy. (i) A shows the brightfield and (B) K-
means image of the cell. (ii) shows the K-means cluster average spectra 
associated with the clusters in the K-means image in the panel above, (iii) shows 
the K-means cluster spectrum associated with polystyrene nanoparticles (A) 
compared with a pure spectrum of polystyrene (B). The Right panels show a 
Principal Component Analysis scatter plot (top), differentiating the green 
(nanoparticle) and light blue clusters (cytoplasm), and the loading of Principal 
Component 1 (Bottom, A), suggesting the local environment surrounding the 
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Figure 2.4 CARS images of the TiO2 nanoparticle distribution in Onchrhynchus 
mykiss gills, (a) forward CARS image showing the nanoparticles, (b) epi-CARS 
image of the gill tissue and (c) merged forward and epi CARS image.             34 
 
Figure 2.5 Epi-CARS images with contrast derived from CD2 and CH2 
resonances in GCPQ nanoparticles at 2100 cm−1 (green) and 2845cm−1 (red) 
respectively. (A) Liver tissue. (B) Stomach tissue samples. (C) shows Jejunum 
tissue imaged with epi-CARS with contrast derived from the CD2 resonance 
(green), SHG contrast derived from collagen (blue) and TPF contrast derived 
from endogenous fluorophores. (D) Ileum tissue imaged with epi-CARS with 
contrast derived from the CD2 and TPF (red) (E) Duodenum imaged with epi-
CARS with contrast derived from the CD2 and TPF (red). (F) Gall bladder 
imaged with epi-CARS with contrast derived from the CD2 resonance (green), 
SHG (blue) and TPF (red).                                                                                 35 
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Figure 4.1: Spectral Constructs based on the normalised difference spectra 
between control and exposed nucleus (A) 10, and cytoplasm 11 (B). Selected Raman 
peaks were used to avoid over complexity in the simulated data; (A) the A form 
peak of DNA at 807 cm-1 and the B form peak at 833 cm-1 and the C-H 
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deformation at 1449 cm-1 (B) the amide 1 band at ~1661 cm-1, the C-C stretch 
intensity at ~939 cm-1 and the tryptophan peak at 731 cm-1.                              83 
 
Figure 4.2: Control dataset taken from Nawaz et al.10; 25 control spectra taken 
from the nucleus of cells not exposed to cis-platin. Spectra have been baseline 
corrected and vector normalised. The inherent spectral variability in the data is 
representative of real experimental conditions. These spectra were then used in 
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Figure 4.3. PLSR modelling against Lethal Concentration for Dataset 1. Top 
panel shows the calibration performance and test dataset (RMSEC 0.49673, R2 
0.99948). Bottom panel shows the performance of the model for the test dataset 
(RMSEP 0.52389, R2 0.99953). Data was split in a ratio of 60:40 calibration and 
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Figure 4.4: Plot of the regression co-efficient following PLSR of Dataset 1 
against Lethal Concentration. The Concentration construct (dashed line) is 
shown in the top panel for comparison with the RC’s in the bottom panel. The 
solid line (bottom panel) shows the regression co-efficient following regression 
of Dataset 1 against Lethal Concentration. The dotted line shows a plot of the 
regression co-efficient following regression of a dataset consisting of just control 
spectra against Lethal Concentration, in effect showing the baseline regression 
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Figure 5.18. Seeded PCA on 2nd derivative spectra from dataset 3 (A) scatter plot 
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phosphatidyl ethanolamine (dashed line) and isolated RNA (solid line), offset for 
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this way were then analysed by CLSA and SCCA.                                             169 
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of component spectrum added to a constant cellular spectrum (points on each 
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graph). The solid black line represents the ideal response which gives an 
indication of the quantitative nature of the technique.                                       171 
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Chapter 1: Introduction: Raman Spectroscopy In 
Nanomedicine and Drug Screening 
1.1 Introduction  
Currently, there is a drive and a need to develop new in-vitro technologies, 
which can be used for a range of applications, including screening for novel 
therapeutic strategies to evaluate the potential risks of nanomaterials as well as 
other toxic compounds. This follows new regulatory practices in both the EU and 
US (EU Directive-2010/63/EU and US Public Law 106-545, 2010, 106th 
Congress)1,2, generally based on the 3 R’s of Russell and Burch3 to replace, 
reduce and refine the use of animals for scientific purposes.   
In-vitro technologies are currently used for a wide range of applications 
such as testing the toxicological potential of certain compounds, identifying novel 
drug candidates as well as the assessment of novel nanoscale compounds4–6. This 
can involve high throughput evaluation of a battery of compounds and 
therapeutics, simultaneously allowing for rapid evaluation of these materials. 
Increasingly, these methods are being optimised to challenge the current 
convention of using animal models. In practice, novel methodologies should 
provide a bio-mimetic platform which can give the same end-point evaluation as 
an animal model at a fraction of the cost.   
Emerging in the field of analytical science is the use of optical techniques 
to characterise biological processes. These include disease diagnostics e.g. 
various cancers7, as well as novel approaches to the evaluation of therapeutics 
and nanomaterials in-vitro, ex-vivo and in-vivo8–10. For the most part, these optical 
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methods rely on the use of fluorescent probes, which, depending on the 
application, may be specifically designed dyes or fluorescent proteins which aim 
to provide an optical visualisation of these processes11–13. Newly developed 
nanoprobes can also be utilised for such purposes, whereby these nanomaterials 
may possess inherent optical properties which allow for a visual characterisation 
of their interaction, for example using microscopic techniques14–16.  
However, in other cases, nanomaterials must be tagged to allow for their 
visualisation e.g. with a fluorescent label17. While this is a viable technique, in 
some instances the fluorescent moiety may become labile, thus creating an 
ambiguity between particle and fluorescent probe18. Additionally, fluorescently 
tagging these materials may alter their properties, and size and charge of the 
nanomaterial are known to affect the interaction19. Asides from these issues, cost 
is also a factor, as the process of fluorescently labelling can become quite 
expensive and therefore there is scope for alternative strategies in the 
investigation of not only nano-bio interactions, but also other biological assays.  
 Increasingly, Raman spectroscopy has emerged as a versatile technique 
which has been used to study a number of different biological processes in a label 
free manner. Applications include disease diagnostics7, cellular studies of drug 
interactions20, as well as mapping nanobio interactions21–24, to list but a few. The 
technique relies on the intrinsic chemical nature of a sample and therefore does 
not require any additional reagents other than the sample (as well as the test 
particle or chemical). Therefore, the technique circumvents the need for 
additional labels and probes to investigate a sample or process.  
 In such applications, there is often a large number of spectra acquired and 
thus interpretation soon becomes a problem. To tackle these issues, multivariate 
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statistical analysis is routinely applied to the data. Depending on the application, 
these methods may be used to distinguish between diseased and non-diseased7,25, 
separate regions of a cell or tissue26–28, extract out features which describe a 
process e.g. in toxicity9 or drug interaction studies26,8.  Fundamentally, these 
methods aim to classify the obtained spectra and thus provide a medium by which 
the information acquired can be grouped and interpreted. 
 Importantly, as with any method which aims to challenge the current 
paradigm, validation is a crucial concern. In most cases, Raman spectroscopic 
analyses are compared to ‘gold standard’ practices, be they in diagnostics 
(histopathological staining) or cellular studies (fluorescent dyes and labels). This 
verification is paramount and allows for a new method to be assessed against its 
established counterpart. 
 In this thesis, Raman spectroscopy is assessed as an in-vitro tool for the 
investigation of nanoparticle-cell and drug-cell interactions. Specifically, the 
multivariate methods which are applied to these problems are investigated. While 
there are a number of challenges faced by the biomedical vibrational spectroscopy 
community, such as sample preparation and instrument fidelity, which come 
under the umbrella term of spectral reproducibility, the multivariate statistical 
methodologies applied to these problems are not without their own caveats.  
 It is thus the aim of this thesis to investigate the application of multivariate 
protocols applied in Raman spectroscopy and explore some of the potential pit 
falls associated with their application. The studies utilise simulated datasets, 
based on real experimental data, which contain known spectral perturbations, 
such that the intricacies of these multivariate statistical methods can be explored 
and the validity, sensitivity and limits of detection can be evaluated.  
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This work also lays down the core foundations of a supervised data mining 
approach in spectral cross correlation analysis, providing a novel approach to 
tracking nanoparticles in cells using Raman spectroscopy. As validation is an 
important concern, the method was compared to other data mining approaches 
such as classical least squares analysis, and further comparisons were made to K- 
Means Cluster Analysis, employed in the original work by Dorney et al24. While 
improvements in specificity were made in the identification of the intracellular 
nanoparticles, it was still not possible to determine whether all spectra in the 
dataset were correctly identified as containing nanoparticles or not, and thus a 
more complex cellular simulation was developed to investigate this issue. 
This thesis is therefore laid out as follows. The background section is split 
into two chapters; chapter 2 is adapted from a review paper published in the 
journal: Nanomedicine, 8(8), 1375 – 1391(2013)29, entitled; “Raman 
spectroscopy in nanomedicine: current status and future perspectives”. The main 
focus here is to look at where Raman spectroscopy has been applied in a 
nanomedical context, focusing on some of the variants (namely SERS, TERS and 
CARS) and also investigating where spontaneous Raman has been applied.  Thus, 
this section aims to give the reader an introduction to the nanomedical field, 
specifically from a Raman perspective, but also introduce some important 
concepts in the fields of nano science and nano biology. 
 Chapter 3 aims to describe the role of multivariate statistical methods and 
their application to Raman spectroscopy in general, but also where these methods 
have been used in the context of Raman cellular imaging, as well as some of their 
applications in exploring nano-bio and drug interactions. Some of the benefits and 
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short comings of these methods will be discussed and the concept of supervised 
approaches in Raman spectral data mining will be introduced.        
Chapter 4 is a reproduction of the journal publication in Analyst, 140, 
2482-2492 (2015)30, and outlines the development of a simulated dataset to assess 
the validity of the partial least squares regression (PLSR) algorithm used in 
biomedical Raman spectroscopy. Based on the experimental results of Nawaz et 
al26, a simulated dataset is generated with known spectral perturbations related to 
both concentration of chemotherapeutic agent and the resultant cytotoxic 
response in-vitro. Both lethal and sub-lethal dose ranges are explored with the 
aim of testing the limits of the PLSR algorithm and also identifying some of the 
potential pit falls of applying this method in Raman spectroscopy.    
Chapter 5 details further investigations of multivariate statistical 
methodologies, namely principal component analysis (PCA), applied to 
biomedical Raman spectroscopy, using simulated data. Furthermore, a novel 
variant of the PCA algorithm is developed, termed seeded PCA (SePCA) and is 
shown to be superior to the standard algorithm for handling continuously varying 
data. Further insights are also garnered on the use of 1st and 2nd derivative spectra 
and the impact this mathematical transformation has on the ability of the 
algorithm to separate and describe the spectral origin of differentiation of spectral 
datasets. 
Chapter 6 describes the development and application of a novel 
supervised data mining approach, spectral cross correlation analysis (SCCA) 
applied to Raman spectral data containing polystyrene nanoparticles, as well as 
specifically designed simulated datasets, based on a publication in Analyst, 137, 
5792-5802 (2012). The approach is compared to a supervised and unsupervised 
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method in classical least squares analysis (CLSA). SCCA is also demonstrated as 
a method to identify other biochemical distributions in the cell, namely lipid and 
RNA distributions  
Chapter 7 outlines the final discussion and conclusions drawn from this 
thesis, highlighting the importance of multivariate statistical analysis in an in-
vitro Raman spectral platform for in-vitro screening technologies, with a 
particular focus on advancing data simulation in this context.  
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Chapter 2: Raman spectroscopy in nanomedicine: 
current status and future perspectives 
 
The following review paper was written by the primary author Mark E. Keating, 
while Hugh J. Byrne, as supervisor, was primarily responsible for editing and 
refining of the text. The format is that of the journal publication, but section and 
figure numbers have been adapted to the format of this thesis.   
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future perspective. Nanomedicine (Lond). 2013 Aug;8(8):1335-51. doi: 
10.2217/nnm.13.108. 
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2.1 Abstract: 
Raman spectroscopy is a branch of vibration spectroscopy which is capable of 
probing the chemical composition of materials. Recent advances in Raman 
microscopy have added significantly to the range of applications which now 
extend from medical diagnostics to exploring interfaces between biological 
organisms and nanomaterials. In this review, Raman is introduced in a general 
context, highlighting some of the areas in which the technique has found success 
in the past, as well as some of the potential benefits it offers over other analytical 
modalities. The subset of Raman techniques which specifically probe the 
nanoscale, namely Surface Enhanced and Tip Enhanced Raman Spectroscopy, 
will be described and specific applications relevant to nanomedical applications 
will be reviewed. Progress in the use of traditional label-free Raman applied to 
investigation of nanoscale interactions will be described, and recent 
developments in Coherent Anti-Stokes Raman Scattering will be explored, 
particularly applications to biomedical and nanomedical fields. 
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2.2 Introduction 
Nanomedicine can be defined as the medical applications of nanotechnology1, 
ranging from the use of nanomaterials in regenerative medicine, drug delivery 
strategies, medical diagnostics and therapeutics and including potential negative 
impacts of nanomaterials to human health, commonly encompassed under the 
term Nanotoxicology. In the context of this review article, nanomedicine is 
viewed from the perspective of how Raman spectroscopy (and its variants) can 
be used in the assessment of the beneficial as well as the potential negative 
impacts of Nanomaterials on human health. Nanomaterials have already found 
uses in a wide range of applications, including anti-microbial paint coatings2, 
textile finishing3, and novel applications in the electronics industry4. Notably, 
biomedical applications are rapidly emerging, ranging from nanoparticle coated 
stents for angioplasty5, contrast agents for diagnostic imaging6,7 and also potential 
drug and gene delivery vehicles8–10. These applications are largely dependent on 
the particular characteristics which nanomaterials and nanoparticles possess.  
These include properties such as increased surface to mass ratio which in turn 
results in an increase in surface reactivity, while novel optical properties 
associated with some classes of nanoparticles are important for applications in 
theranostic imaging and subsequent monitoring of drug delivery. However, whilst 
these technologies show promise, it is important to be able to visualise how the 
materials behave in situ, and particularly in the biological context, to be able to 
characterise their interactions and toxicological effects, be they in-vitro or in-vivo. 
While it has been highlighted that comprehensive characterisation of the physico-
chemical properties of nanoparticles is imperative, changes to these properties, 
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such as aggregation state and effective surface chemistry, can play a critical role 
in their modes of interaction and action11. Equally, to understand the modes of 
action and optimise efficacies, monitoring and understanding changes to the 
biological environment is critical, not only on a cellular level but also when 
considering the systemic responses. 
Considering the system as a whole, one must be able to track a particle or 
material from initial exposure or administration through to the site of action and 
on to assimilation, degradation or excretion. At each step in this process, one must 
be able to access and visualise the efficacy by which the particles can overcome 
certain barriers to successful administration. These can vary from the route of 
exposure, assessing whether the particle causes toxicity, particle retention (e.g. 
via the enhanced permeability and retention (EPR) effect), or removal for 
circulation via uptake by the reticuloendothelial system (RES), accumulation of 
the nanoparticles over time, non-specific interactions, the efficacy with which the 
particle reaches its desired location etc.. 
Ideally, what is required is a method which can successfully characterise 
these processes, firstly in fundamental in-vitro cytological and ex-vivo 
histological studies and ultimately in more realistic in-vivo applications. This 
method should be capable of identifying the particle or material of interest while 
simultaneously being able to access the surrounding environment while 
measuring the efficacy of the probe or nanocarrier and/or the physiological 
response of the organism.   
There exists a large range of analytical methods which can be used in the 
classification and characterisation of nanomaterials. These include scanning and 
transmission electron microscopy (SEM and TEM), atomic force microscopy 
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(AFM), other label free optical methods such as differential interference contrast 
(DIC) and dark field microscopy and fluorescent microscopy methods based on 
intrinsic nanoparticle or external label fluorescence, to name but a few. However, 
these methods are not without certain drawbacks which limit to some extent their 
applicability and effectiveness. 
Firstly, both AFM and SEM can be considered as primarily surface 
sensitive techniques, while, when TEM is coupled with serial sectioning and 
ultra-microtomy, it has been used for 3D reconstructions and tomography12,13. 
However, these processes are time consuming, costly and laborious. In addition, 
EM requires a particle to have contrasting electron density compared to its 
environment to allow for a particle to be visualised, which renders it ineffective 
for many “softer” polymeric nanoparticles.  EM does not allow live cells to be 
imaged and, as it requires extensive sample processing, it provides only a limited 
scope for rapid or routine investigation of nanomaterials in-vitro. What EM and 
AFM do provide is the capability of imaging beyond the optical diffraction limit.  
More recently developed optical based methods, so-called super resolution 
microscopy, have become available that allow for imaging beyond this limit14–16. 
However, their use has been limited in the field of nanomedical sciences as of yet.  
In contrast, standard fluorescent based microscopy has been used 
extensively in nanoparticle studies16–20. Confocal Laser Scanning (fluorescence) 
Microscopy (CLSM) has become a standard in the toolbox of techniques for in -
vitro cytommetry 21. Although the technique is limited in resolution to hundreds 
of nanometers, it can potentially detect fluorescence emission from, and therefore 
the location of, individual nanoparticles. Penetration depths in-vivo can be 
extended through two photon excitation techniques and/or NIR fluorophores22,23. 
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In the visible region, a range of fluorescent assays and labels are commercially 
available to probe a range of physiological processes in-vitro, such as lyso and 
mitotracker used for labelling lysosomes and mitochondria24. Intrinsically 
fluorescent nanoparticles such as inorganic semiconductor quantum dots have 
been developed for similar applications25 and surface functionalisation of these 
types of materials has contributed to understanding the dependence of uptake and 
intracellular trafficking on surface chemistry26. Many similar studies have been 
performed with fluorescently labelled nanoparticles27,28 which are commercially 
available in a range of sizes and surface functionalities. However, not all 
nanoparticles can be easily fluorescently labelled. Furthermore, it is not clear that 
the transport mechanisms of smaller nanoparticles, fluorescently labelled with 
anionic moieties, are the same as their unlabelled counterparts29. Critically, there 
have been reports that labelled nanoparticles can release the dye into the 
surrounding biological environment, and so the distribution of fluorescence 
within the cell does not necessarily represent the presence or subcellular 
distribution of the nanoparticles30–32. Other label free optical microscopy 
techniques are also limited by the type of particle which can be visualised i.e. only 
metal based particles are effective for dark field and DIC microscopy33.    
Raman spectroscopy has been proposed as a method for monitoring 
nanomaterials in biological systems, as it potentially provides a label free, non-
invasive probe of the nanoparticle itself, the local environment and the physiology 
of the organism34. Over the past decade, Raman spectroscopy has been applied to 
a range of biomedical areas, including cancer diagnostics35, toxicity studies36, 
atherosclerosis37 and investigation of skin38,39. Importantly, what Raman provides 
is not just a method for differentiation between a diseased and non-diseased state, 
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it is based on characterisation of the (bio) chemical nature of a sample, based on 
the characteristic vibrations of the molecular bonds of the constituent 
components. Raman is a form of vibrational spectroscopy, which in itself is a 
subset of a more general umbrella term of spectroscopy. The vibrations are 
characteristic of the molecular structure and, in polyatomic molecules, give rise 
to a spectroscopic “fingerprint”. The spectrum of vibrational energies can thus be 
employed to characterise a molecular structure, or changes to it due to the local 
environment or external factors. The Raman spectrum is thus a truly label free 
signature of the nanoparticle. Vibrational energies typically fall in the mid 
Infrared (IR) region of the electromagnetic spectrum and are quite commonly 
probed using IR absorption spectroscopy. Raman in many ways can be viewed as 
a complementary technique to IR spectroscopy; whereas IR involves absorption 
of radiation, Raman is an inelastic scattering technique whereby the incident 
radiation couples with the vibrating polarisation of the molecule and thus 
generates or annihilates a vibration. For a vibration to be active in IR 
spectroscopy, a change in dipole is required, whereas to be Raman active, a 
change in polarisability is required. As a rule of thumb, vibrations of asymmetric, 
polar bonds tend to be strong in IR spectra, whereas Raman is particularly suitable 
as a probe of symmetric, nonpolar groups. Importantly, this results in the O-H 
bonds of water being strong absorbers in IR spectroscopy, whereas they are 
relatively weak Raman scatterers. This allows for samples to be investigated in 
an aqueous environment and thus the technique of Raman spectroscopy more 
readily lends itself to live cell in-vitro40 or in-vivo41 measurement. As the 
vibrational spectrum is measured as a frequency (or energy) shift from that of the 
incident radiation, Raman spectroscopy can be performed across the UV, visible 
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or near infrared spectral regions, and thus can benefit from the technologies 
available and advances made for confocal optical microscopy.    
 A number of variants which are based around the physical principal of 
Raman spectroscopy exist. Spontaneous Raman can take the form of Stokes 
Raman scattering and anti-Stokes Raman scattering, the former resulting from the 
creation of a vibration in a material, characterised by a decrease in the incident 
photon energy (frequency), the latter from the annihilation of vibration, 
characterised by an increase in the incident photon energy. If the incident 
radiation is resonant with an electronic absorption of the analyte, the Raman 
signal can be resonantly enhanced by several orders of magnitude. The use of 
Resonant Raman Spectroscopy (RRS) in biomedical systems has been limited, 
however, due to associated photochemical degradation phenomena and the 
generation of fluorescence which can swamp the Raman signal of the overall 
sample.   
 Other variants of these two techniques with increased sensitivities for 
more molecularly specific characterisation have been developed. These include 
resonant Raman spectroscopy, coherent anti Stokes Raman spectroscopy 
(CARS), tip enhanced Raman spectroscopy (TERS) and surface enhanced Raman 
spectroscopy (SERS).  The majority of these techniques have been applied to 
nanomedical applications; however, two of these methods deal inherently with 
the nanoscale, namely TERS and SERS. Although Raman is fundamentally an 
optical technique and is thus similar to confocal optical microscopy, limited to 
spatial resolution of the order of hundreds of nanometres, nanometre resolution 
can be obtained through localised enhancement processes. This localised 
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enhancement led to the initial interest in the prospect of the use of Raman 
spectroscopy to probe the specific environment of the nanoparticle.  
This article will outline the applications of the various Raman 
spectroscopy based technique in the broad area of Nanomedicine. As they are 
nano-specific, the use of SERS and TERS techniques will be presented initially, 
while the increasing interest in the use of truly label free spontaneous Raman and 
Coherent Anti-Stokes Raman Spectroscopy (CARS) in nanomedical applications 
will then be explored. In Raman spectroscopy, the sensitivity, spatial resolution 
and penetration depth and required scan rates depend on technique employed, 
resonance conditions and even the instrumental set-up (microscope objective, 
grating, laser power). In the respective section describing each modality, 
examples of the state of the art in nanomedical applications are provided. The 
future perspectives attempts to address routes beyond the current state of the art. 
A more detailed description of the historical origin and basic principles of the 
Raman scattering process can be found in numerous excellent text books42–46 and 
review articles47–49. A comparison of Raman and IR spectroscopies for 
biomedical applications can be found in 50.  
2.3 SERS 
The phenomenon of surface enhanced Raman spectroscopy was described as 
early as 197451,52, and is understood to arise from a localised increase in the 
coupling between the electromagnetic field of the incident radiation and the 
polarisation of the analyte in the presence of optically induced surface plasmons 
on a metal surface. Increases of Raman intensities as high as 1010 have been 
reported53, although the spatial range of enhancement is only of the order of tens 
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of nanometers. The enhancement process can be achieved using a number of 
substrates including roughened metallic surfaces, structured metal arrays and 
specially imprinted surfaces.  
Notably, the SERS effect can be induced through the use of metallic 
nanoparticles and nano colloid aggregates. SERS is a direct enhancement of the 
Raman signal and in the case of nanoparticles this occurs in the immediately 
surrounding local vicinity. The true principal that governs SERS enhancement is 
not fully understood, although the effect has largely been attributed to an 
electronic enhancement due to local fields generated by surface plasmon 
resonances at the metal surface. Alternatively, the enhancement has been 
attributed to a charge transfer process between the analyte and the surface, 
although it is probable that the processes act in tandem54. The technique of SERS 
in a biomedical context is reviewed in greater detail in the following papers55–57.   
 Nanoparticles and aggregates which are used for SERS enhancement 
typically consist of a metallic nanoparticle, most commonly gold and silver. Quite 
often, these particles are subsequently modified via surface functionalisation 
which can include targeting moieties designed for specific applications, 
especially as nanosensors. The particle may also be labelled with a Raman 
reporter moiety which allows for identification of the particle in the biological 
milieu. Using these particles, it has thus been possible to apply SERS to a number 
of biological scenarios, which include diagnostic studies in-vitro, ex-vivo58,59 and 
in-vivo60,61 , novel bio assays62–64 as well as cellular studies.  
SERS has been proposed as a method for understanding how 
nanomaterials behave in a cellular environment, important in the study of the 
fundamental interactions of nanoparticles in the context of toxicology, drug 
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delivery or contrast agents for diagnostics.  In 2009, Kneipp et al. proposed that 
by using SERS it would be possible to probe the chemical nature of the subcellular 
environment and the intracellular distribution of biomolecules. This work was 
extended by incorporation of Raman reporters which allowed for localisation of 
the SERS probe within the cell, leading to chemical probing of sub cellular 
nanostructures65–68. For example, in 2010, the group showed how a SERS 
nanosensor was capable of investigating pH changes in a cell throughout the 
stages of the endocytic pathway of the nanoparticle probe. The study was based 
on changes in the pH of the local environment in different cellular organelles 
which can be monitored via changes in the pH sensitive nanoprobe over time69.   
Other cellular studies have also investigated the possible use of SERS in 
the investigation of cell surface receptors associated with cancer. In one such 
study, Kong et al 2012 used organometallic SERS active nanoparticles which 
were targeted to live cells expressing the EGFR (epidermal growth factor 
receptor). The SERS nanoparticles were shown to be capable of specific targeting 
to the cell surface and offered increased sensitivity in comparison to other 
imaging modalities70.  Figure 2.1 a-e, shows oral squamous cell carcinoma 
(OSCC) cells expressing the epidermal growth factor receptor (EGFR), c and e 
show the SERS image generated by CO at 2030cm-1 and protein at 1600cm-1 
respectively. The targeting is verified in Figure 2.1 f – j in a non-EGFR expressing 
cell line SKOV3 (ovarian carcinoma) and in Figure 2.1 k-p by blockage of the 
EGFR using an EGFR antibody.  
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Figure 2.1 shows (a, f, k) the brightfield image, (b, g, l) the darkfield image of the 
nanoparticles, c, h, m) the SERS image of CO at 2030cm-1, (d, I, o) merged SERS 
and brightfield, and (e, j, p) the SERS image generated using the protein band at 
1600cm1. a – e shows OSCC cells, f – g SKOV3 cells not expressing EGFR and k 
– p OSCC cells treated with anti-EGFR. Reproduced from 70 
 
Another demonstrated application of SERS in is the analysis of human 
serum. Lin et al., in 2011, demonstrated the power of SERS coupled with 
multivariate analysis to distinguish in a non-invasive way between patients 
previously diagnosed with colorectal cancer and control patients with 100% 
diagnostic sensitivity and specificity71. 
In-vivo SERS is also possible, and has been demonstrated as a potential 
labelling method for a number of applications. SERS has been used in-vivo to 
investigate how enhancement of the Raman signal can be used as a method for 
tumour detection. Qian et al. showed how EGFR targeting PEGylated gold 
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nanoparticles labelled with a Raman reporter where capable of >200 times greater 
signal generation in the infrared compared to that of near infrared fluorescent 
quantum dots, which allowed for the possible identification of small tumours at 
penetration depths of ~ 1-2cm60. Other in-vivo applications of SERS have also 
been explored, including an in-vivo study of inflammation in mice72, 
demonstrating improvements over fluorescent based methods. SERS has also 
been shown to be capable of single molecule detection in-vitro, a sensitivity 
which sets it apart from spontaneous Raman spectroscopy73.    
More complex Raman based investigations have also taken advantage of 
the surface enhancement process. Techniques such as deep penetrating spatially 
offset Raman (SORS) have been combined with nanoparticle based SERS in 
SESORS7475. In brief, in the SORS technique, introduced in a paper by Matousek 
et al, the Raman spectra are collected at positions spatially offset from the point 
of incidence of the probe laser beam. Rather than using microscopic objectives 
for delivery and collection, fibre probes are used. By moving the collection point 
away from the probe launch site, contributions from the surface Raman photons 
are diminished and those of Raman photons from deeper within the sample are 
increased. Using multivariate statistical methods, it is possible to reconstruct 
spectra from the different layers with a much greater depth of penetration than a 
traditional confocal microscopy setup76. Depth sensitivities of up to several 
millimeters are now achievable and examples of emerging applications include 
non-invasive diagnosis of bone disease, cancer and monitoring of glucose levels77 
SESORS uses this same principal, taking advantage of the surface enhancement 
of the Raman signal from metallic nanoparticles embedded within the sample. In 
a recent publication by Xie et al, SESORS was used to identify bisphosphonate-
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functionalized nanotags on bone through 20mm of porcine tissue78. This study 
highlights the increasing potential for in-vivo applications which SORS and 
SESORS may have, in the field of nanomedicine.      
SERS has enjoyed increasing popularity over the past decade, particularly 
since the emergence of as increasing range of nanoprobes. However, the uptake 
rates and mechanisms as well as the subsequent trafficking may be specific to the 
nanoparticle type, size and surface chemistry. Most SERS probes are specifically 
designed for a target application and so are labels themselves for the SERS signal. 
Furthermore, the molecular specificity of the surface enhancement process is not 
well understood. Therefore, a truly label free method for generic monitoring and 
characterising the cellular uptake and subcellular localisation of nanoparticles in 
general is still required. 
TERS another method for generating enhancement of the Raman signal. 
Like nanoparticle based SERS, this method is also based on probing of the 
inherent nanoscale environment of the sample in close proximity to a nanoprobe 
and will therefore be discussed.  
2.4 TERS  
Tip Enhanced Raman spectroscopy, or TERS, is a method which combines 
Raman spectroscopy and scanning probe microscopic techniques such as AFM.  
TERS, like SERS, is a method to enhance the Raman signal and, in principle, the 
mechanism of enhancement is the same. Scanning probe tips have dimensions of 
the order of tens of nanometers or less, and when metal coated, surface plasmon 
resonances can be optically induced, similar to the case for metallic nanoparticles. 
In TERS, the topography of the nanoscale environment of samples can be probed 
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by bringing the tip into close proximity with the area of the sample to be probed, 
but the Raman signal from the environment being probed by the tip is selectively 
enhanced by several orders of magnitude, swamping the spontaneous Raman 
from the remainder of the illuminated spot.  Therefore TERS is a method which 
allows for very small areas or even individual molecules to be probed in a label 
free manner. 
TERS has been used to investigate viral cell interaction79, cytochrome-c 
states in isolated mitochondria80, lipid and protein organisation in artificial cell 
membranes81, as well as hemozoin crystal formation inside malaria infected red 
blood cells, as shown in Figure 2.282. Figure 2.2. A –C show AFM images of 
infected red blood cells, highlighting the hemozoin crystals inside the cellular 
vacuole in C. Figure 2.2 D shows the TERS spectrum from the edge of the crystal 
deposits showing characteristic peaks associated hemozoin and the profile is 
compared to the SERS and RRS spectra of β-hematin in F and G . This study 
highlights TERS as a nanoscale technique with can be used to probe very specific 
areas which may have implications in disease. In this instance, TERS provides a 
potential method to study the interaction of quinoline anti-malarial drugs which 
are believed to preferentially bind to the edge of hemozoin crystals.    
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Figure 2.2 TERS probing hemozoin crystal formation inside malaria infected red 
blood cells. A – C show AFM images of infected red blood cells. D shows the 
TERS spectrum for the edge of the hemozoin crystal deposit, E is the spectrum of 
the tip following retraction from the cell, F SERS spectrum of β-hematin, G 
resonance Raman (RR) spectrum of β-hematin. Reproduced from 82.  
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TERS has also been used in the investigation of the interaction between 
cells and nanoparticles. Alexander and Schultz (2012) were able to show the 
interaction of individual antibody conjugated nanoparticles and cell surface bio 
molecules using TERS, with a similar sensitivity to SERS83.  
However, as TERS requires the use of AFM tips to enhance the signal, the 
method is restricted to being a surface classification technique and thus is of 
limited use for intracellular or indeed ex-vivo or in-vivo tissue analysis. While 
surface enhanced methods provide promise in a number of nanomedical areas, 
there are some caveats associated with these methods. Firstly, the probe must be 
capable of generating a surface enhancement of the Raman signal; this is only 
applicable to certain types of gold and silver particles or coated tips, as well as 
nanoaggregates of these metals. Additionally, these techniques require a 
considerable expertise in synthetic chemistry and design of probes or tips for 
specific target applications. Furthermore, reproducibility of the enhancement is 
also a concern, in particular with TERS, were the reproducibility of the tip 
characteristics is important in gathering reproducible spectra. Therefore it is 
important to consider that, while surface enhanced methods have been shown to 
be capable of nanoscale accuracy, these methods are heavily reliant on 
specifically designed nanoparticle sensors or probes and tips which in some way 
dilutes the label free aspect which spontaneous Raman spectroscopy provides.     
2.5 Spontaneous Raman Spectroscopy 
To differentiate it from the numerous variants of Raman spectroscopy which have 
emerged over the past decades, including SERS and TERS, the originally named 
phenomenon of Raman spectroscopy is now frequently called spontaneous 
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Raman spectroscopy. Spontaneous Raman spectroscopy has been used 
extensively over the past decades for a range of biomedical applications and is 
emerging as a viable alternative to gold standard protocols in medical diagnostics. 
Other uses include investigations in blood84 and serum samples85, investigations 
of human skin38,39, cellular investigations86–88, in-vivo41 and ex-vivo35 
characterisations as well as studies of interaction of nanoparticles36. 
 Importantly, these applications using Raman spectroscopy rely on the use 
of data analytical methods which aid in the classification and understanding of 
the data which has been acquired. This may entail the use of chemometric 
methods to cluster a data set so that one can see a cell or tissue as a distribution 
of similar spectra in a map. Multivariate statistical methods can be employed for 
the separation of two different classes of spectra e.g. a diseased and non-diseased 
state. A full description of such analytical methods is beyond the scope of this 
review. However, it is important to highlight how Raman spectroscopy and 
multivariate data mining approaches are commonly used together to investigate 
the biochemical nature of samples.  Some good examples of where these 
statistical methods have been applied to Rama hyperspectral datasets can be found 
here87,89,90. 
 Despite the extensive development of Raman spectroscopy for biomedical 
applications and the specific use of SERS using nanoprobes, not many studies 
have explored the use of spontaneous Raman spectroscopy for nanomedical 
applications. Of the reports that exist, some have aimed to look at probing cells 
for a toxic response36,91, others have aimed to look at how nanomaterials behave 
in a cellular environment34,92 and some have looked at degradation patterns of 
potential nanoparticle drug carriers93.  
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 The potential of Raman spectroscopy as a toxicological screening method 
has been demonstrated for the case of carbon nanotubes and their effects on 
human cells in-vitro. Kneif et al 2010, showed how the cellular spectral signatures 
differed between control and exposed cells due to changes in specific Raman 
spectral peaks of the cell nuclei. This method provided a way of investigating the 
toxic response of cells to nanomaterials in a truly label free manner, compared to 
more typical dye based cytotoxicity testing. In addition to detecting differences 
in response due to nanoparticle exposure, it was also possible to statistically 
compare the dose dependent responses of the Raman signatures with other gold 
standard toxicity tests, demonstrating the potential of the technique as a 
quantitative high throughput screening assay36.  
In a different type of study by Dorney et al 2012, the aim was to 
demonstrate the potential of Raman spectroscopy to visualise and investigate the 
interaction of polystyrene nanoparticles in cells. The purpose was to use these 
particles, which are often used as a standard in toxicity studies, as a model particle 
for further applications using Raman spectroscopy. In brief, the Raman 
spectroscopic signatures of the cells were mapped with a step size of 0.75µm over 
a region which contained both nuclear, perinuclear and cytoplasmic regions of 
the cell. Using a combination of K-means clustering and principal component 
analysis, it was possible to identify the localisation of the particles inside cells 
based on the intrinsic polystyrene signature and also to probe the chemical 
characteristics of the local subcellular environment34. A highlight of the results in 
shown in Figure 2.3 for cells incubated for 24hrs with polystyrene nanoparticles. 
The image in Figure 2.3 (i) shows the brightfield image (A) and the K-means 
image constructed for the Raman hyper spectral dataset (B). The polystyrene 
 29 
nanoparticles are shown as green pixels in the image and the K-means average 
spectra are shown in Figure 2.3 (ii) A-D. The cluster associated with the green 
pixels clearly shows characteristic peaks associated with polystyrene when 
compared to a pure sample spectrum, Figure 2.3 (iii) A and B. The light blue and 
green clusters were then compared using Principal Component Analysis showing 
that the nanoparticles are located in lipid rich regions of the cell, which, by 
comparison with confocal fluorescence microscopy, was demonstrated to be the 
endoplasmic reticulum. 
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Figure 2.3. Identification of intracellular distributions of polystyrene 
nanoparticles using Raman spectroscopy. (i) A shows the brightfield and (B) K-
means image of the cell. (ii) shows the K-means cluster average spectra 
associated with the clusters in the K-means image in the panel above, (iii) shows 
the K-means cluster spectrum associated with polystyrene nanoparticles (A) 
compared with a pure spectrum of polystyrene (B). The Right panels show a 
Principal Component Analysis scatter plot (top), differentiating the green 
(nanoparticle) and light blue clusters (cytoplasm), and the loading of Principal 
Component 1 (Bottom, A), suggesting the local environment surrounding the 
nanoparticles is lipid rich. Reproduced from 34. 
 
Another recent study by Chernenko et al94 aimed to investigate how 
different types of deuterated liposomal nanoparticles are distributed in cells.  
More specifically, it aimed to investigate how different chemical compositions 
affected how the liposomes associated with the mitochondrion. Notable in this 
study is the use of deuterated liposomes to enhance the ability to differentiate 
liposomes from endogenous lipids in the cell, based on the fact that the C-D 
vibrational frequency is significantly down shifted from that of the C-H stretch of 
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the very abundant intrinsic macromolecules of the cell. Another paper by the same 
group also looked at the degradation of polymeric nanoparticles over time in cells 
and concluded that poly lactic-co-glycolic acid (PLGA) and polycaprolactone 
(PCL) drug delivery systems are degraded and incorporated into the late 
endosomes of the Golgi system, based on spectral changes associated with the 
specific degradation patterns of the nanocarriers93.   
 Spontaneous Raman spectroscopy has therefore already been 
demonstrated to be a chemically specific method for investigating nanoparticle 
interactions and also to probe the biochemical nature of cells.  Notably, a number 
of biochemical features can be accessed simultaneously without the need for 
fluorescence or other labelling methods, or for costly cytotoxicological assays. It 
should be noted, however, that, based on current technologies, spontaneous 
Raman is a relatively weak effect, thus highlighting the attention which surface 
enhanced techniques such as SERS and TERS have received. Relatively weak 
signals can be compensated for by longer acquisition times, with maximum 2D 
scan times of the order of 40-80 mins for a 50µm*50µm area with a step size of 
500nm for cellular data95. However, these scan speeds are largely dependent on 
the required signal to noise ratio and the step size used in image acquisition. For 
these reasons real-time imaging has not been realised to date.  
Ultimately, for in-vivo applications, penetration depth is also an important 
consideration. In Raman microscopy, sensitivities are optimised by choice of 
objective, providing optical spatial resolution but limited penetration depth (~1-
50µm). As Raman spectroscopy is an optical technique, the penetration depth is 
largely determined by the choice of wavelength of the source laser, and optimally 
this can be chosen in the near infrared region where tissue has a transmission 
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window. Absorption is largely governed by that of chromophores such as melanin 
(in skin) or haemoglobin across the visible, and by the overtones of OH vibrations 
in the near infra red regions. Scattering is an additional loss mechanism, but the 
development of Spatially Off-Set Raman Spectroscopy 77 using fibre probe rather 
than microscope objective delivery and collection optics, has exploited the fact 
that the signal from the deeper layers is scattered to a greater extent, to improve 
penetration depth sensitivities. CARS is another label free type of Raman 
scattering which can be used to probe bio and nanomedical scenarios and in recent 
years has seen a growth in applications in cells, tissues and in-vivo imaging. Using 
single wavelengths, imaging of large areas can be achieved at video rates.  
2.6 CARS 
Coherent anti-Stokes Raman spectroscopy (CARS) is a form of Raman 
spectroscopy whereby the anti-Stokes shifted Raman signal is used to probe the 
molecular bonds within a sample. The coherent process takes advantage of a third 
order non-linear optical phenomenon by which three beams are used to probe the 
sample.  A fixed pump laser beam, a tunable probe beam are set at a frequency 
difference which is exactly equal to the frequency of a specific molecular 
vibration, resulting in the coherent build-up of a scattered signal on the anti-
Stokes side of the pump laser frequency96,97. The signal can be orders of 
magnitude larger than a spontaneous Raman signal. Thus, CARS can be used to 
rapidly generate images of a particular biochemical distribution and therefore can 
be used in the generation of video rate image sequences of cells and tissues. To 
generate a full spectroscopic signature, however, the pump beam has to be tuned 
such that the difference frequencies scan the vibrational spectrum, a process 
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which can take considerable time, under current technological constraints. The 
nonlinear process is furthermore intensity dependent, requiring costly and 
notoriously temperamental short pulse lasers, whereas spontaneous Raman can 
be conducted with conventional steady state lasers.  
In a biomedical context, the technique has been used to investigate a 
number of phenomena, also in conjunction with other methods such as immuno-
fluorescent labelling. Primarily, CARS has been used in the study of the C-H 
stretch region which is most commonly associated with lipids in living organisms. 
Examples include the use of CARS for the study of atherosclerotic lesions98, 
intracellular trafficking99, drug delivery100, cancer metastasis101, quantitative 
imaging of lipid distributions in living Caenorhabditis elegans102 as well as 
imaging of the axonal myelin both in-vivo and ex-vivo103,104 CARS has also been 
used in the assessment of nanomaterials. Notably ,the technique has been used to 
study particle interaction in biological organisms, receptor mediated particle 
uptake105 as well as the effects of particle size and coating on zebra fish 
embryos106. Moger et al107 used CARS to investigate the interaction of metal 
oxide nanoparticles within the gills of rainbow trout, Onchrhynchus mykiss. They 
were able to show in a label free manner the translocation of TIO2 particles across 
the epithelial membrane and into the capillaries in fish gill tissue. This is shown 
in figure 2.4, which illustrates the forward (a) and epi-CARS images (b) of 
exposed fish gills. The merged image shows the localisation of the particles in 
the gill tissues, revealing particle clumps in green.   
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Figure 2.4 CARS images of the TiO2 nanoparticle distribution in Onchrhynchus 
mykiss gills, (a) forward CARS image showing the nanoparticles, (b) epi-CARS 
image of the gill tissue and (c) merged forward and epi CARS image. Images 
reproduced from 107. 
The method has also recently been used to investigate the mechanisms of 
oral uptake of Quaternary Ammonium Palmitoyl Glycol chitosan (GCPQ) 
nanoparticles. In this study, the particles were deuterated to shift the CH2 
stretching vibration located at 2840cm-1 to a CD2
 stretching vibration of 2100cm-
1. This allows for CARS to be carried out in the so called ‘silent region’ of the 
cell. Additionally second harmonic generation and two photon fluorescence were 
used to image the tissue containing nanoparticles.  In doing this, Garrett et al. 
were able to examine chitosan uptake and recirculation in the gut by being able 
to target the nanoparticles with cellular precision to the gastrointestinal tract, liver 
and gall bladder, providing novel insights in the role of enterocytes and bile 
recirculation regarding chitosan nanoparticles100,108. Figure 2.5 shows the 
identification of the deuterated nanoparticles in green (2100cm-1), which are 
highlighted by the arrows. Figure 2.5A and 2.5B show liver and stomach tissue 
respectively, with the C-D2 resonance being used to identify the deuterated 
nanoparticles (2100cm-1) in green and the C-H2 (2845cm
-1) in red. Figure 2.5C 
shows a multimodal label free imaging approach combining CARS imaging 
(green), second harmonic generation (SHG) and two photon fluorescence (TPF) 
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in imaging nanoparticle interaction with jejunum tissue. Figure 2.5D and 2.5E 
show the use of a combination of CARS and TPF to image the ileum and 
duodenum respectively, while Figure 2.5F shows a combination of CARS, SHG 
and TPF of the gall bladder. These approaches show not only how CARS can be 
used to probe nanoparticle interactions, but also highlight how multiple imaging 
approaches can be combined in multimodal approaches to give different types of 
information building towards a more complete picture.      
 
Figure 2.5 Epi-CARS images with contrast derived from CD2 and CH2 
resonances in GCPQ nanoparticles at 2100 cm−1 (green) and 2845cm−1 (red) 
respectively. (A) Liver tissue. (B) Stomach tissue samples. (C) shows Jejunum 
tissue imaged with epi-CARS with contrast derived from the CD2 resonance 
(green), SHG contrast derived from collagen (blue) and TPF contrast derived 
from endogenous fluorophores. (D) Ileum tissue imaged with epi-CARS with 
contrast derived from the CD2 and TPF (red) (E) Duodenum imaged with epi-
CARS with contrast derived from the CD2 and TPF (red). (F) Gall bladder 
imaged with epi-CARS with contrast derived from the CD2 resonance (green), 
SHG (blue) and TPF (red). Reproduced from100  
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Surface enhancement can also be exploited in the CARS format. Surface 
enhanced CARS (SECARS) has been used in conjunction with nanoparticles and 
has been shown to be capable of achieving greater signal enhancement than that 
of SERS or CARS alone. For biomedical applications, it has also been used for 
the detection of single molecules of deoxyadenosine and deoxyguanosine 
monophosphate (dAMP and dGMP)109 and has also been used in immuno-
histochemistry studies110. 
2.7 Conclusions and Outlook 
This article has attempted to provide an overview of the current state of the art of 
the developing applications of Raman spectroscopic techniques in Nanomedicine. 
A recent review has dealt more broadly with the applications of these techniques 
in the investigation of the interaction of nanomaterials with complex biological 
systems111. The development of biomedical applications of vibrational 
spectroscopy, both Raman and IR, has been extremely active for the past two 
decades and more and the challenges to nanomedical applications are intrinsically 
linked, as indeed they are to those of the fundamental understanding of nanobio 
interactions in general. 
As a molecular specific tool, Raman spectroscopy can potentially aid 
significantly to the understanding of nanobio interactions in-vitro. Even before 
interaction with the cell, it has been argued that the biological identity of the 
nanoparticle is determined by the surface coatings of the dispersion medium, the 
co-called protein corona112. While SERS active nanoparticles can be employed to 
probe this interaction acellularly, there is evidence that the nanoparticle medium 
interaction is very specific to the surface characteristics and size, and thus the use 
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of truly label free spontaneous Raman spectroscopy may lead to broader insights. 
In this context, the increased sensitivity of TERS may be of significant benefit. 
SERS has however demonstrated that the surface coating can evolve significantly 
after endocytosis of the nanoparticle 111, and this is a critical consideration in the 
bioavailability of surface functionalities, including release of active ingredients, 
which have been specifically designed for nanomedical applications.  
As an confocal optical microscopic technique, Raman holds all the 
benefits of confocal fluorescence techniques, but has the potential advantage of 
being truly label free, adding the promise of reduced cost and sample processing 
requirements. SERS probes have demonstrated the potential to probe nanoparticle 
uptake, trafficking as well as the local environment, but these probes need to be 
specifically chemically tailored for the given application can so the technique 
cannot be considered to be truly label free. Spontaneous Raman spectroscopy is, 
on the other hand, an intrinsically weak phenomenon and cellular mapping is 
often a prolonged processes. Nevertheless, a number of cellular studies have been 
conducted which, although not specifically probing nanoparticles, may have 
implications in future nanomedical applications. For example, some studies have 
shown the application of Raman to drug delivery investigations113,114 while other 
studies have identified sub cellular structures such as the mitochondrion as well 
as lipid rich regions which may be associated with the Golgi and endoplasmic 
reticulum88. Klein et al. used image registration and immuno-fluorescence to 
verify the locations of cellular organelles and also as a means of extracting the 
spectra which were specifically associated with the organelle115. These studies 
could be extended to look at nanoparticle trafficking studies, colocalizing the 
particle to an organelle in a label free manner, without using fluorescently labelled 
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nanoparticles or organelle stains. Although spontaneous Raman studies are 
commonly conducted on fixed cells, live cell spectral profiling has been 
demonstrated40. Image analysis is ultimately dependent on the reliability of 
multivariate chemometric techniques and simulated model systems can prove 
invaluable in validating their accuracy83. Increased acquisition rates can be 
achieved by systems custom designed for biological applications, and CARS 
potentially offers a route towards routine in-vitro screening of intracellular 
nanobio interactions, although its ability to rapidly screen the full spectrum is 
currently limited by the (tuneable) laser source technologies and applications are 
thus restricted by the need to identify specific spectral marker bands. 
In terms of disease diagnostics, ex-vivo applications of Raman 
spectroscopy have received much attention. For the range of Raman modalities, 
however, mapping of large areas of tissue biopsies also suffer from issues of weak 
signals (spontaneous), specifically targeted probes (SERS), surface sensitivity 
(TERS) or the need for specific spectral markers (CARS). As a chemically 
specific probe, however, Raman techniques are particularly suitable for analysis 
of biomarkers of disease in biological fluids7374  and this suitability is readily 
extended to applications in nanomedicine.  
Raman scattering is fundamentally an optical technique and in-vivo 
applications are thus limited by the ability to access the area of interest. For 
dermal analysis, custom designed systems are commercially available which 
exploit the near infrared transmission window of skin, although, in a microscopic 
format, the penetration depth is further limited by the delivery optics, typically to 
some hundreds of microns. Advances in SORS have increased the depth 
resolution, and such technologies could prove invaluable tools for analysis of 
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transdermal nanodrug delivery or environmental exposure to nanoparticles. As an 
optical technique, Raman spectroscopy readily lends itself to endoscopic 
probes116, however, and recent advances in such in-vivo probes may significantly 
impact on biomedical applications of Raman spectroscopy, including, inevitably 
Nanomedicine. 
2.8 Future Perspectives 
The field of nanotechnology is set to grow ever rapidly as new applications and 
avenues of research are explored over the coming decade. Crucially, 
characterisation and visualisation methods in a medical setting must develop in 
tandem, to access the applicability of such nanotechnology. Raman spectroscopy 
represents a method proven in the field of disease diagnostics and biomedical 
imaging and thus by extension holds the capability to progress the field of 
nanomedicine.  
Spontaneous Raman spectroscopy provides a versatile and truly label free 
method which has seen success in a number of different medical applications, 
most notably in disease diagnostics. Key enabling technological developments in 
this context include endoscopic and other in-vivo probes. Relatively Low signal 
strengths currently limit the technique to small areas and/or long scan times, 
however, and continuing improvements in signal throughput and detector 
sensitivities are important.  EU Directives limiting the use of animal models will 
put increasing emphasis on the development of in-vitro screening methods and 
Raman is a potential candidate for high content analysis of, for example, the 
efficacy and mode of action of novel chemotherapeutical agents of toxicants. The 
high optical resolutions obtainable make Raman particularly suitable for acellular 
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or subcellular studies of nanobio interactions. As the sensitivity of the Raman 
technique is intimately linked with the multivariate statistical data analysis 
methods, the quantitative specificities of these methods must be established. This 
can only be done if the true result is known, and in this context the use of 
specifically constructed model datasets may provide a quantifiable insight into 
how far Raman spectroscopy can be pushed in both a medical and nanomedical 
context.  
SERS provides increased sensitivities to probe the nanoscale environment 
surrounding metallic nanoparticles. Although the technique is not truly label free, 
with the increased sensitivities achievable as well as the targeting potential of 
such probes, SERS may provide alternative imaging strategies for disease 
diagnostics in-vivo, as well as provide enhanced methods for the monitoring of 
human fluids such as serum and other metabolic excretions ex-vivo. SERS in-
vitro may also prove a useful tool in probing the nature of the so called protein 
corona of nanoparticles in biological media and thus provide valuable insights 
into the surface behaviour of nanomaterials in a biological setting. Other 
enhancement methods such as TERS also provide novel insights into the 
nanoscale environment although they are limited by being mainly a molecular or 
surface specific technique.   
Coupling these advances in spontaneous and surface enhanced Raman 
with the development of SORS and SESORS, some of the shortcomings in signal 
generation and depth penetration of Raman spectroscopy in-vivo may be 
overcome. In addition to the development of endoscopic and needle based probes 
which will increase access to the point of interest, realistic applicable in-vivo 
Raman studies in nanomedicine may not be too far away. CARS provides a 
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method which is capable of video rate scan speeds. However, as of yet the 
technique is not a spectroscopic imaging technique as it only allows for the 
probing of one particular wave number or vibrational marker at a time. The 
technique therefore requires a clearly identifiable biomarker for imaging, which 
may not be the case for all biomolecules.  A CARS system that could provide a 
spectrum of the finger print region of the sample with similar real time imaging 
capabilities would be ideal. Specifically for CARS to progress as a spectroscopic 
imaging modality, advances in laser technology such as rapidly tunable lasers will 
need to develop in tandem. These advances would then open a myriad of 
applications for CARS imaging along the lines of spontaneous Raman imaging.   
2.9 Executive Summary 
Raman Spectroscopy: Raman spectroscopy is a well-established chemical 
analysis technique finding increasingly broader applications, particularly in 
biochemical analysis and disease diagnostics.  
Surface/Tip enhanced Raman Spectroscopy: The techniques of SERS and 
TERS specifically probe the nanoscale and, although TERS is a topical/surface 
technique, SERS probes have already been used extensively for in-vitro and in-
vivo studies. SERS probes are normally chemically functionalised according to 
the specific target, and so the technique is arguably not truly label free. 
Spontaneous Raman Spectroscopy: As a truly label free technique, 
(spontaneous) Raman spectroscopy, coupled with multivariate analytical 
techniques potentially provides a probe of nanoparticles in cells/tissue, their 
nature of their local environment, and physiological changes. Unenhanced, the 
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signals are however relatively weak, and large scale mapping can be time 
consuming. 
Coherent anti-Stokes Raman Spectroscopy: CARS is a nonlinear optical 
technique which is increasing in prominence for biomedical applications. Tuned 
to a specific vibrational frequency, it can scan large areas (cm2) at video rates. 
Currently, however, it is not a spectroscopic technique and does not avail of the 
full biochemical information available, but relies on the presence of a specific 
spectral marker.  
Outlook: The range of modalities of Raman spectroscopy potentially hold great 
promise for biomedical and nanomedical applications, although many technical 
challenges remain. 
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Chapter 3 Introduction to Raman spectroscopy and 
multivariate analytical methodologies applied to spectral 
datasets. 
The following chapter contains sections from a journal article published in the 
Chemical Society Reviews, entitled: Spectral pre and post processing for Infrared 
and Raman spectroscopy of biological tissues and cells which Hugh J. Byrne was 
primary author, Peter Kneif was second and contributing author, Mark E. Keating 
was third contributing author with sections 3.2 – 3.9 used in the manuscript and 
Franck Bonnier was final contributing author.   
 
Byrne HJ, Knief P, Keating ME, Bonnier F. Spectral pre and post processing for 
infrared and Raman spectroscopy of biological tissues and cells. Chem Soc Rev. 
DOI: 10.1039/c5cs00440c.  
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3.1 Introduction to Raman spectroscopy 
Upon interaction with a material, light can be reflected, absorbed, or scattered. 
Raleigh scattering (elastic scattering) is when the scattered light is of the same 
frequency as the incident light. Raman scattering (inelastic scattering) is a result 
of light that is scattered by a material, whereby its frequency differs from that of 
the incident light, as a result of the interaction of a photon with the vibrations of 
a molecule. 
In Raman scattering, the energy increase or decrease from the excitation is related 
to the vibrational energy spacing in the ground electronic state of the molecule, 
and therefore the Raman shift of the Stokes and anti-Stokes lines are a direct 
measure of the vibrational energies in a molecule. In Stokes Raman scattering, 
the molecule starts out in a lower vibrational energy state and, after the scattering 
process, ends up in a higher vibrational energy state. Therefore, the interaction of 
incident light with the molecule creates a vibration in a material and the scattered 
photon is reduced in energy. 
In anti-Stokes Raman scattering, the molecule begins in a higher vibrational 
energy state and, after the scattering process, ends up in a lower vibrational energy 
state. Thus, a vibrational quantum in the material is annihilated as a result of the 
process and the scattered photon has an increased energy. The frequency 
differences between the Raman lines and the incident lines are characteristic of 
the scattering substance and are independent of the frequency of excitation. 
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The Raman effect arises from the coupling of the induced polarisation of 
scattering molecules, which is caused by the interaction of the electric field vector 
of the electromagnetic radiation with the molecular vibration modes. Light of 
frequency (ωL) produces a polarisation in a material given by equation 3.1 
P(ωL) = χ(ωL) E0cos ωLT                Equation 3.1 
where P is the polarisation, ωL is the frequency of incident light, E is the electric 
field and χ(ωL) is the polarisability or susceptibility, normally considered a 
constant of the material associated with its electronic properties. However, at a 
finite temperature, a material is not at equilibrium and atoms will vibrate about 
there equilibrium position, R, along the normal coordinates with frequency ωK, in 
accordance with a simple harmonic oscillator approximation. The displacement 
from equilibrium can be explained by equation 3.2 
ΔR(t) = ΔRcos(ωkt)    Equation 3.2 
The susceptibility to polarisation thus oscillates about its equilibrium value χ0 and 
can be represented by equation 3.3 
χk(t) = χ0 + Δ χkcos(ωkt)         Equation 3.3 
The polarisation now has the form as illustrated in equation 3.4 
P(ωL, ωk) = χ0(ωL)E0cosωLt +Δ χkE0cos(ωL)tcos(ωk - δk)   
 Equation 3.4 
where δk takes into account any phase difference between the molecular vibration 
and the electric field oscillation. This may be written as equation 3.5 
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P(ωL, ωk) = χ0(ωL)E0cosωLt +1/2ΔχkE0(COS((ωL -ωk)t - δk) + cos((ωL +ωk)t + δk))   
 Equation 3.5 
Thus, the polarisation has the form 
P = P(ω0) + P(ω0 - ωk) + P(ω0 + ωk)      
 Equation 3.6 
An oscillating dipole will reradiate at the oscillation frequency, and thus the 
scattered light has three components. P(ω0) gives rise to Raleigh scattering. P(ω0 
- ωk) corresponds to the subtraction of a vibrational quantum from the photon 
energy and the creation of a vibration and gives rise to the Stokes lines of the 
Raman spectrum.  P(ω0 + ωk) corresponds to the addition of a vibrational quantum 
to the photon by the annihilation of a vibration and results in the anti-Stokes lines 
of a Raman spectrum 
3.2 Introduction to Multivariate Methods Applied to Raman 
Spectral Datasets.  
Multivariate methods have become invaluable to a wide range of fields, including 
geology, pharmaceutical science, pharmacology, astrophysics, imaging, 
chemistry and the list goes on. Importantly, these methods allow for complicated 
and also in some instances very large datasets to be analysed and in effect they 
reduce the dimensionality and complexity of the data allowing for meaningful 
information to be extracted.  
 Specifically considering vibrational spectroscopic datasets, multivariate 
methods allow analysis of multiple spectra simultaneous and interdependently. 
This then allows for comparisons to be made between spectra and groups of 
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spectra within a dataset and to identify trends these may contain e.g. spectral 
markers of disease in control and non-control patients, identification of 
nanoparticle containing spectra, response to external agents such as drug or 
toxicants etc. 
 A Raman dataset usually consists of groups of spectra, which, depending 
on the sample and study being carried out, can be a set of random points, averaged 
spectra which can be the function of an external stimulus such as radiation, a 
chemical agent, nanoparticle etc. As the main focus of this work is centred on 
nanoparticle localisation and in-vitro drug screening using Raman spectral 
microscopy, multivariate statistical methodologies applied in this area will be 
discussed in more detail.  
 In Raman spectral microscopy, the dataset consists of a group of spectra 
which have been acquired via point mapping or raster scanning of a sample which 
may be cells or tissues, in in-vitro or in-vivo studies. As an imaging tool, much 
like fluorescent confocal laser scanning microscopy (CLSM), the sample has been 
scanned point by point, resulting in a dataset or in the case of spectral imaging a 
spectral hypercube. Unlike the simplicity of standard fluorescent imaging, 
whereby the dataset contains only one value per pixel, spectral hypercubes (as the 
name suggests) contain multiple data points per pixel which correspond to the 
spectrum acquired at that location. Similarly when spectra are acquired point by 
point each spectrum corresponds to the location sampled, without the spatial 
localisation achieved when imaging, with the benefit of the user knowing where 
the sample was acquired i.e. nucleus, cytoplasm etc. 
 As an imaging modality, to generate an image from this dataset, one must 
reduce the number of data points at each pixel to a single value. The simplest way 
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to achieve this is to form an image from one particular wavenumber in the 
spectrum. However, this method is somewhat flawed in that, if the peak in 
question corresponds to multiple biomolecules in a sample, it would be difficult 
to provide an accurate image of one particular composition. Nevertheless, in some 
instances, for example if a sample has a very distinctive peak, this may be the 
simplest way to generate an image. In a similar way, separation and classification 
can be achieved by single wavenumbers or ratios using point by point acquisition, 
although the multivariate nature of the technique is somewhat diluted if only a 
single wavenumber is used. Again if there is a prevalent change across the dataset 
this may be the simplest way to analyse the spectra.    
 As necessary, a myriad of methods have been developed to overcome this 
problem in spectral analysis. Using Raman spectroscopy as an example of where 
these methods are applied, clustering methods such as hierarchal clustering 
analysis (HCA), k-means clustering analysis (KMCA) and fuzzy c-means 
clustering (FCM) have been used to cluster spectra into groups and then based on 
these groups or classes, images and scatter plots can thus be generated following 
analysis. These clustering methods can be described as ‘hard clustering’ methods, 
in that each spectra is assigned a unique value and if a spectra has been assigned 
to one cluster it cannot be assigned to another.   
 Other methods have also been applied to Raman spectral analysis, 
including principal component analysis (PCA) and vertex component analysis 
(VCA). Both have been used for a number of applications. PCA has been used 
quite extensively to separate different sets of data based on the spectral variance 
present. This may be in a diagnostic setting and also in a spectral imaging sense. 
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VCA has also been used in this capacity although primarily in a Raman imaging 
setting.  
 Factor analysis methods have also been applied to Raman spectral 
datasets e.g. matrix factorisation (MF). In some instances, these methods are used 
to generate model spectra which in turn can be combined with other analytical 
approaches such as classical least squares analysis (CLSA) to evaluate, in a semi 
-quantitative way, the weighted contribution of each model spectrum to a 
particular spectrum for both images and individual groups of spectra. 
 This section of the introduction aims to give a brief description of some 
of the data mining approaches used to analyse vibrational spectroscopic data, 
focusing specifically on Raman spectroscopy, although examples from other 
spectral modalities such as IR spectroscopy will also be discussed in this context. 
The techniques which are explored more extensively in the thesis (e.g. KMCA, 
CLSA, PLSR and PCA) are described in more detail. 
3.3 K-Means Cluster Analysis 
K-means clustering analysis (KMCA) is a statistical method which aims to 
partition data into clusters based on similarity. K-means aims to minimise the sum 
of distances between spectral vectors 𝑆𝑗
𝑖 and cluster centroids mk where J spectral 
vectors originally are randomly assigned to belong to a given cluster k with 
centroid mk
1
, see equation 3.7.  
     ∑(𝑆𝑗
𝑖 −  𝑚𝑘) Equation 3.7 
Firstly, the method chooses a number of seed locations which serve as initial 
centroid locations in the dataset. Once a data point is assigned to one of the seed 
locations, it changes to a centroid which serves as a mean value of that cluster. 
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The assignment of data points to clusters is often based on the Euclidean distance 
between data point and centroid, although other methods of calculating the 
distance also exist2. After each spectrum has been assigned to a centroid, the 
distance is then recalculated between each point and centroid to see if any points 
are closer to another centroid location, whereupon, if the point is closer to another 
cluster centroid, then it is reassigned and both cluster centroids are changed as a 
result. This process is completed for all data points until there is no movement 
between clusters.   
 So, considering K-means from a Raman spectroscopic imaging 
perspective, an initial number of seed locations is chosen. The spectra are then 
assigned to one of the seed locations. Once all spectra have been assigned, the 
mean spectrum or centroid is calculated and the distance between each spectrum 
and centroid is calculated. The spectra are then reassigned if necessary and the 
process is iterated until no spectra change groups. Figure 3.1., shows a diagram 
highlighting the main steps in the K-means clustering algorithm. 
 In Raman spectroscopy, KMCA has seen a number of uses to separate 
spectra into clusters based on spectral similarities. As a Raman imaging tool, 
KMCA aims to separate each spectrum acquired in the image and assign it to a 
cluster. This assignment is termed ‘hard’ in that each spectrum is only assigned 
to one cluster. A good example of KMCA in Raman spectroscopy is shown in the 
work by Dorney et al3. Here, KMCA was used to identify regions in the Raman 
dataset which correspond to polystyrene nanoparticles, and differentiate them 
from neighbouring cytoplasm, as well as the nucleus and nucleolus. KMCA has 
also seen uses in other areas of Raman spectroscopy and spectral imaging such as 
the characterisation of skin layers. Good examples of KMCA as an spectroscopic 
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imaging reconstruction technique exist, the technique having been used in the 
investigation of a wide range of samples including tissue sections4, cells5,6 and in 
the analysis of human skin7–9.    
While this method has been shown to be useful in partitioning spectra into 
clusters, it is important to highlight that the method is not without certain caveats. 
Firstly, as the initial choice of centroid location can be subjective, the 
reproducibility of the method can in some instances be called into question i.e. if 
the initial starting point of the analysis changes then it is possible to end up with 
different results, so in practice if multiple datasets need to be compared all data 
should be analysed using the same centroid locations as these will change if 
analysis is carried out separately. Secondly, looking at the method to assess 
spectral imaging, each spectrum is assigned to only one cluster, and the cluster is 
represented by the average of all constituent spectra. As a Raman spectrum may 
represent a number of different biological entities in differing quantities, KMCA 
may be correct in grouping a spectrum based on lipidic distribution. However, it 
may misclassify a spectrum which also contains a small amount of another 
cluster’s biochemistry. There is no weighting element introduced into the 
analysis, so one spectrum must belong to only one cluster even if multiple 
biochemical constituents are present. Thirdly, the number of clusters chosen is 
subjective and thus dependant on the user, if the incorrect number of clusters are 
chosen then spectra could be miss classified based on the loading from that group. 
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Figure 3.1 Schematic diagram outlining KMCA. 
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3.4 Fuzzy C – Means Clustering 
Fuzzy C-means clustering is a method which is similar to KMCA in that it also 
assigns spectra to centroids in the datasets. However, unlike KMCA, the method 
is a soft clustering method, whereby each point or spectrum in the dataset is 
assigned a value from 0 to 1 for each particular cluster centre, with the value 
closest to 1 being representative of the cluster centre and 0 having no assignment. 
The algorithm developed by Bedzek et al10, to calculate the degree of membership 
for each spectrum in the dataset results in a vector of the format 𝑁𝑥𝑁𝑦 ∗ 𝐶 since 
each spectrum has C membership values. The co-efficients which describe 
membership to a particular cluster are defined by the following equation. 
 𝑈𝑖𝑁𝑆 =
1
∑ (𝑑𝑖𝑁𝑆/𝑑𝑐𝑁𝑆)
2/(𝑚−1)𝑐
𝑐=1
  Equation 3.8 
Where 𝑈𝑖𝑁𝑆 is the membership of the sample Ns in one cluster, where 𝑑𝑖𝑁𝑆 and 
𝑑𝑐𝑁𝑆 are the distances to the i
th and cth cluster centres and m is the fuzziness factor 
between w and ∞.Therefore, by analysing the C centroid spectrum it is possible 
to extract chemical information which describes each reconstructed image.  FCM 
has seen some usage in Raman spectroscopy although primarily as an imaging 
method 5,6.  
3.5 Hierarchal Cluster Analysis 
Hierarchal clustering analysis is another method which is commonly used for 
clustering spectral data and generating images. There are two main forms of 
HCA, agglomerative and divisive. Agglomerative HCA is the more commonly 
used method. Briefly, this method starts out with each data point or spectrum in 
a separate group or cluster. The method then aims to group each data point 
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together in an iterative process until there is only one cluster which contains all 
the data points. It is then possible to construct an image based on how these 
clusters are linked together. Often, the data can be represented using a two 
dimensional dendrogram which shows the linkage between each cluster.  Divisive 
HCA on the other hand starts off with each spectrum in one cluster and then aims 
to separate each data point into one cluster. An example dendrogram is shown in 
Figure 3.2 An important point in relation to HCA is that, once a group of spectra 
has been assigned to a cluster or in the case of the agglomerative method merged 
into a cluster, the spectrum cannot be reassigned, unlike KMCA where the spectra 
can move clusters if closer to another centroid. This means that HCA results in a 
very definite grouping of spectra into clusters.  
 HCA is like KMCA in that the method is deemed to be a hard clustering 
method with each spectrum being assigned to a specific group. From an image 
reconstruction perspective and classification, this means that each pixel again can 
only be assigned to one specific biochemical grouping, which may not be 
reflective of the actual Raman dataset. HCA has been used in as a classification 
method in  number of studies which include cellular studies6 as well as in the 
investigation of vibrational spectroscopy in diagnostics11.      
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Figure. 3.2. Showing a HCA dendrogram and both divisive and agglomerative 
clustering. Adapted from12.   
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3.6 Vertex Component Analysis  
Vertex component analysis is another multivariate statistical method which is 
used in Raman spectral analysis13. The algorithm makes an assumption that, 
contained within the dataset, are pure endmember spectra which in turn can be 
used to describe all the other spectra in the dataset. From this, abundance plots 
can be generated via a linear combination of endmember spectra and constructed 
into images which are described by the biochemical information contained in 
these endmember spectra.  
Assuming a linear mixing scenario each observed spectral vector is given 
by: 
𝑟 = 𝑥 + 𝑛 = 𝑀𝛾𝛼 + 𝑛 
       Equation 3.9 
Where r is an L-vector (L is the number of bands), M = [m1,m2……mp] is the 
mixing matrix (mi denotes the ith endmember signature and p is the number of 
end-members present in the covered area), s = γα(γ is a scale factor modelling 
illumination variability due to surface topography), 𝛼 = [α1, α2…… αp]T is the 
abundance vector containing the fractions of each end-member (.)T stands for the 
vector transposed) and n model system additive noise.13 
Recently, VCA has seen a number of applications in hyperspectral 
imaging using both IR and Raman spectroscopy, with applications including 
Raman histopathological imaging and also cellular studies including nano-bio 
interactions4,14 Importantly, while this method can be used quite readily to 
reconstruct biochemical regions in the cell, like all methods it may be prone to 
error. Firstly, as highlighted in a paper by Chernenko et al.14, endmember spectra 
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may contain mixtures of different biochemical components and while this may be 
reflective of the actual nature of the sample, may lead to inaccuracies in 
interpretation. Additionally, the method makes a large assumption that the most 
extreme spectra in the dataset are the most reflective of pure component spectra, 
which may not be the case in complex biological spectra.  
3.7 Principal Component Analysis  
PCA is a method which aims to reduce the dimensionality of the data to describe 
the variation present in a dataset, whereby the first principal component is a 
description of the maximum variance present in the dataset, the second describes 
the second most variance…etc. The principal component scores can then be 
described by the loading vector which is an explanation of this variance. In a 
Raman spectroscopy context the scores represent values which correspond to a 
loading spectrum which contains peaks, both positive and negative which 
explains the spectral variation in the dataset.  
 This tool can be quite useful for providing a method to separate spectra 
into groups e.g. diseased and non-diseased15. It has also been used to reconstruct 
images6,16, i.e. a variance plot based on the loadings plot. However, as these 
loadings plots may often contain a number of spectral features corresponding to 
different cellular biochemistry, interpretation can be difficult and it is quite 
possible to misinterpret. Bonnier et al have shown that pairwise PCA of clusters 
identified by KMCA can provide a clearer picture of the specific biochemical 
differences between region17.   
In this thesis Seeded Principal Component Analysis (SePCA) is 
introduced as a novel multivariate analysis variant to address some of the 
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limitations of the application of PCA in bio-spectroscopy in systematically 
varying datasets. Using simulated data based on experimental spectra of in-vitro 
exposure to varying doses of the chemotherapeutic agent, cis-platin, standard and 
SePCA are compared, firstly based on their ability to differentiate the responses 
to different exposure doses, and secondly to assess the accuracy of the loadings 
that are used to describe the systematic variations of biochemistry underlying the 
differentiation. Further insights are also garnered on the use of 1st and 2nd 
derivative spectra and the impact this mathematical transformation has on the 
ability of the algorithm to separate and describe the spectral origin of 
differentiation of spectral datasets. The implications of this novel variant of PCA 
are discussed in the context of screening for drug efficacy in-vitro as well as 
biomedical classification for disease diagnostics. 
3.8 Partial Least Squares Regression 
Partial least squares regression (PLSR) is an analytical technique which aims to 
match a test data set to a series of targets. In brief, the method aims to create a 
model dataset which relates a spectral dataset to a series of test points or targets 
(i.e. concentration, dosed). The spectral data (X matrix) is thus related to the 
targets (Y matrix) according to the linear equation; 
𝑌 = 𝑋𝐵 + 𝐸 
      Equation 3.10 
where B is a matrix of regression coefficients and E is a matrix of residuals18. A 
good practical example of this method in action in Raman spectral data is outlined 
in two studies by Nawaz et al.16,17, in which the aim was to investigate the 
capability of Raman as a technique to study drug interactions in cells and the 
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physiological response. Looking specifically at cis-platin as an example 
chemotherapeutic drug, these studies were able to extract information relating to 
drug action in the cells via regression of the Raman dataset against 
cytotoxicological data and dose. Features were extracted from the Raman spectra 
which correspond to changes to protein conformation and structural alterations of 
DNA19,20.  
 Importantly, while these studies show the potential of Raman 
spectroscopy and PLSR as tools for studying drug interaction, PLSR used in this 
capacity is only relevant if the processes studied are in themselves linear. 
However, most pharmacological actions are non-linear processes and thus using 
a linear method to model a non-linear process may be subject to error. Thus, 
additional forms of validation of these methods in a spectral setting are necessary. 
 In this thesis, PLSR is investigated using simulated datasets based on 
previously published data. In this way the application of the PLSR algorithm is 
investigated and the limits and sensitivities are explored using a simulated dose 
and cytotoxicological target dataset, providing a methodology for the assessment 
of multivariate approaches used for Raman in-vitro screening.    
3.9 SVM 
Support vector machines is a classifier which aims to partition data to give a 
separation between control and sample. Generally, the algorithm is used in 
conjunction with PCA, whereby the coefficient values are used to build a model 
which is then used to classify samples. Initially data with a known classification 
is used to train the model i.e. control vs. cancer. Once the model has been trained, 
samples with an unknown grouping are classified based on their affinity for each 
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group. In this way, it is possible to classify samples as one group or the other 
when the grouping is unknown.  
 
3.10 Concluding Remark 
While the list of methods is far from exhaustive, it highlights some of the commonly 
used analytical methods in Raman spectral analysis. Some of these methods have 
certain caveats associated with them and thus may be prone to error for certain 
applications. In the following chapters, some of the possible issues associated with 
these methods in an in-vitro Raman setting are explored, primarily using simulated 
datasets which are based on real experimental data. Novel variants and methods are 
also explored to tackle some of the issues which have arisen while investigating these 
methods, with the central thesis focusing on the use of simulated datasets in assessing 
the validity, accuracy and applicability of multivariate statistical methodologies for in-
vitro Raman screening and beyond. ‘ 
In the following chapters, some of the possible issues associated with these methods 
in an in-vitro Raman setting are explored, primarily using simulated datasets which are 
based on real experimental data. More detailed descriptions of the underlying theories of 
PLSR analysis (Chapter 4), PCA (Chapter 5) and CLS analysis (Chapter 6) are 
provided. Novel variants and methods are also explored to tackle some of the issues which 
have arisen while investigating these methods, with the central thesis focusing on the use 
of simulated datasets in assessing the validity, accuracy and applicability of multivariate 
statistical methodologies for in-vitro Raman screening and beyond. 
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Chapter 4 Multivariate statistical methodologies applied in 
biomedical Raman spectroscopy: Assessing the validity of partial 
least squares regression using simulated model datasets.   
 
The following chapter contains sections from a journal article submitted to Analyst, 
entitled: Multivariate statistical methodologies applied in biomedical Raman 
spectroscopy: Assessing the validity of partial least squares regression using simulated 
model datasets which Mark E. Keating was primary author and responsible for data 
analysis, writing and formatting of the paper, Haq Nawaz was second author and 
contributed code and spectral data, Franck Bonnier was third author and co-supervisor 
and Hugh J. Byrne was final author and supervisor.   
 
Keating ME, Nawaz H, Bonnier F, Byrne HJ. Multivariate statistical 
methodologies applied in biomedical Raman spectroscopy: assessing the validity 
of partial least squares regression using simulated model datasets. Analyst. 2015 
Mar;16;140(7):2482-92. doi: 10.1039/c4an02167c. 
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4.1 Abstract  
Raman spectroscopy is fast becoming a valuable analytical tool in a number of 
biomedical scenarios, most notably disease diagnostics. Importantly, the 
technique has also shown increasing promise in the assessment of drug 
interactions on a cellular and subcellular level, particularly when coupled with 
multivariate statistical analysis. However, an important consideration, both with 
Raman spectroscopy and the associated statistical methodologies, is the accuracy 
of these techniques and more specifically the sensitivities which can be achieved 
and ultimately the limits of detection of the various methods.  The purpose of this 
study is thus the construction of a model simulated data set with the aim of testing 
the accuracy and sensitivity of the partial least squares regression (PLSR) 
approach to spectral analysis. The basis of the dataset is the experimental spectral 
profiles of a previously reported Raman spectroscopic analysis of the interaction 
of the cancer chemotherapeutic agent cis-platin in an adenocarcinomic human 
alveolar basal epithelial cell- line, in-vitro, and is thus reflective of actual 
experimental data. The simulated spectroscopic data is constructed by adding 
known perturbations which are independently linear in drug dose, as well as 
cytological response, experimentally determined by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assay. It is 
demonstrated that, through appropriate choice of dose range, PLSR against the 
respective targets can differentiate between the spectroscopic signatures of the 
direct chemical effect of the drug dose and the indirect cytological effect it 
produces.  
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4.2 Introduction  
Over the past couple of decades, vibrational spectroscopy (in particular Raman 
and infrared absorption) has emerged as a powerful tool for biomedical 
applications. The numerous studies explore applications such as disease 
diagnostics3–6, cellular imaging7–10, the study of drug1,2,11and nanoparticle 
interactions12–14 on a cellular and sub-cellular level, to name but a few. In both 
modalities, the spectrum of tissue or cells contains a wealth of information, 
representing as it does the combined molecular fingerprints of the ensemble of 
biomolecules contained in the sample, and only in the simplest of cases can a 
valid interpretation be made by visual inspection of the spectrum. Multivariate 
statistical methods are thus critical in the analysis, interpretation and 
representation of the complex information contained within. However, given the 
critical nature of the outcomes of the application, whether in terms of medical 
diagnostics or in preliminary screening of drug efficacy and action mechanisms, 
it is imperative that the combination of spectroscopic techniques and multivariate 
analysis are rigorously and quantifiably validated. Such validation can also 
establish realistic limits to what is often purported as a high content screening 
methodology. To this aim, the use of simulated datasets based on experimental 
studies can play a crucial role14,15. 
 A multitude of multivariate analytical methods exists, each of which aims 
to simplify complex bio-spectroscopic information and provide a tool with which 
to draw conclusions about the state of the sample. These include Principal 
Component Analysis (PCA), Linear Discriminant Analysis (LDA), Vertex 
Component Analysis (VCA), Spectral Cross Correlation Analysis (SCCA), K-
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means Clustering Analysis (KMCA), Hierarchal Cluster Analysis (HCA) to name 
but a few. Importantly, there also exists a number of variants of these methods 
which differ slightly and can give, in some instances, different answers14,16,17.  
 Recently, regression modelling (e.g. Partial Least Squares Regression, 
PLSR) has seen a number of biomedical uses in both Raman and IR 
spectroscopies. The core idea of using this method is to investigate the spectral 
variability as a function of a systematic conditional change such as  radiation 
dose18 or viral infection19.  PLSR can be employed to construct predictive models 
for spectral response as a function of the target variable. Therefore, an unknown 
dose or degree of infection can be determined from its spectrum, having obvious 
potential clinical applications. Furthermore, feature selection techniques such as 
PLSR co-efficient, Jack-Knifing (JK) and genetic algorithms, amongst others20, 
can be employed to identify the most statistically relevant spectral changes, such 
that the biological mechanisms underlying the spectral changes can explored and 
understood. Importantly, there are many variants of the PLSR algorithm and, in 
some instances; hybrid methods which use a combination of two statistical tools 
in order to extract relevant chemical information have been employed. Although 
these methods have been applied to a wide range of studies, the details are beyond 
the scope of this paper although good examples can be found in literature1,2,18,21–
24 
The potential of Raman spectroscopic microscopy for initial screening of 
chemotherapeutic efficacy and mechanism of action has been demonstrated by 
Nawaz et al.1,2,23. Taking the interaction of cis-platin with the human lung 
adenocarcinoma cell line, A549, in-vitro, as an example, PLSR of Raman 
spectroscopic datasets was reported to identify and differentiate the direct effects 
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of cis-platin on the cellular biochemistry as a function of drug concentration 
(dose) and the resultant toxicological response as measured by the MTT 
cytotoxicity assay. This simultaneously provides a parallel gold standard 
technique to compare to the spectroscopic endpoint as well as range finding for 
the initial dose response curve i.e. establishing values of Inhibitory 
Concentrations (IC) etc. In an operational model of pharmacological agonism, the 
former is a linear process, whereas the latter results in the more complex 
sigmoidal response of cell populations to drug exposure25. PLSR against the drug 
concentration returned changes in the Raman peaks associated with both 
conformational and chemical changes in DNA, while changes to the lipid and 
protein distributions were dominant when the data was regressed against the 
cytotoxicological end point, indicating the biochemical changes associated with 
the resultant cytological response to the interaction with cis-platin. The statistic 
relevance of the results were confirmed using the JK approach. 
The potential to differentiate the direct chemical effects from the 
subsequent cytological responses opens the way to the use of the techniques to 
visualise and interpret the mode of action of chemotherapeutic agents intracellular 
and to quantify the efficacy to produce the desired cellular response in a single 
truly label free measurement. The emergence of ever higher throughput 
spectrometers would enable real-time and time resolved visualisation of the 
respective processes as they evolve. Notably, however, while the studies of 
Nawaz et al. show great promise towards this end, the technique is as yet un-
validated. The expected changes in the spectra with concentration and 
toxicological endpoint are inferred, based on prior knowledge about the biological 
action of cis-platin in the model in-vitro system. This leads to a difficulty when 
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trying to confirm the validity of the method or compare two different methods to 
quantitatively assess the sensitivity, accuracy and specificity of the technique. 
Here, we aim to validate the application of these methodologies using 
simulated datasets based on the previously published experimental results of 
Nawaz et al.. In particular, we aim to test the ability of PLSR to model and thus 
extract spectroscopic variations (based on the regression co-efficient) which vary 
systematically as a function of different targets. Thus, the study will confirm 
whether the method is capable of extracting and differentiating spectroscopic 
features which differ based on linear or non-linear changes of the targets. 
Additionally, the accuracy or fidelity of the method in extracting systematically 
varied features will be explored as the spectral perturbations introduced decrease 
in magnitude, exploring the sensitivity of the method. Thus, the overarching aim 
is to establish the validity of the algorithms applied to Raman spectral datasets 
containing changes pertaining to the direct and indirect effects of the anti-cancer 
drug cis-platin in-vitro. For the purposes of this study, we propose the use of a 
modelled simulated dataset. The dataset is constructed based on experimental 
observations, but the systematic spectral variation that is introduced is known 
precisely and thus an exact and complete assessment of the method can be carried 
out.  
4.3 Methods   
4.3.1 Experimental  
Experimental results were obtained as described in previous publications by 
Nawaz et al1,2 which investigated Raman spectroscopy as a tool to study cis-
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platin-cellular interactions in-vitro. The experimental methods are described in 
detail in the publications, but are summarised in brief as follows. 
Human lung adenocarcinoma (A549) cells were routinely cultured at 37 
°C, 5 % CO2 in DMEM F12 supplemented with 10% FBS, 1% pen/strep and 2mM 
l-glutamine. Cells were cultured until 70-80% confluence and plated on quartz 
substrates for Raman spectroscopy. A standard MTT assay, using a concentration 
range of 0.05µM – 50µM, was used to assess the toxicity of cis-platin to provide 
a comparison to Raman spectroscopy. This was carried out in standard 96 well 
plates and experiments were all completed in triplicate. This range resulted in a 
sigmoidal variation in cell culture viability over the range ~90% to ~20%, from 
which the Inhibitory Concentration (IC50) of cis-platin in A549 cells in-vitro was 
determined to be 1.2 ± 0.2 µM.  
Cis-platin, at varying concentrations in the range 0.05 µM - 50µM, was 
added to cells and Raman microscopic measurements of cells exposed to each 
dose, including unexposed control, were acquired at a source wavelength of 
785nm for both nuclear1and cytoplasmic regions2 . The PLSR approach was used 
to model the spectroscopic data as well as to select and distinguish the relevant 
features indicative of the chemical effects of cis-platin and the cellular response 
to cis-platin via a regression against dose and the MTT cytotoxicity endpoint 
respectively. By examination of the regression co-efficient, it was possible to 
discern the major features responsible for model construction.  
In this work, these experimental spectral datasets are employed to 
construct semi-realistic simulated data to probe the reliability, sensitivity and 
quantitative nature of these methods when applied to drug-interaction studies. 
More details of the experimental set up can be found in Nawaz et al. 1,11 
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4.3.2 Partial Least Squares Regression  
PLSR is a multivariate statistical method which aims to establish a model that 
relates the variations of the spectral data to a series of relevant targets. The 
spectral data (X matrix) is thus related to the targets (Y matrix) according to the 
linear equation Y = XB +E, where B is a matrix of regression coefficients and E 
is a matrix of residuals. The PLSR algorithms used in this study have been 
previously published elsewhere1,2,18,22 and are based on scripts written in house 
using Matlab 7.2 (The Mathworks Inc.). The algorithm allows for the construction 
of a regression model which can be used to predict the outcome in a number of 
different situations. In this case, the examples used are concentration and MTT 
response, and therefore the algorithm can be used to predict for example the 
toxicological response of a particular drug dose.   
Latent variables (LV’s) in PLSR modelling are a series of underlying 
variables which aim to describe the behaviour of the modelled system. The exact 
number of latent variables which are necessary to build an entirely accurate model 
is not known a priori. However, it is one of the goals of PLSR models to 
accurately predict the number necessary to build a robust and accurate model26. 
Predicting the number of LVs which will build an accurate model is usually 
achieved during the cross validation step, typically using the root mean squared 
error of cross validation (RMSECV) as a metric for latent variable selection.  
4.3.3 Spectral Constructs 
Spectral constructs were generated for the purpose of imparting a known 
perturbation to the dataset which could be systematically varied to evaluate the 
capability of the PLSR modelling to accurately predict and extract spectral 
variations correlated to a known external variable, in this case, drug dose and the 
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resultant cytological changes. Using the original datasets of Nawaz et al., derived 
from the nuclear and cytoplasmic regions, specific spectral changes were 
identified in the mean difference spectra of a 3µM exposed cell population versus 
the unexposed control (Figure 3, of reference 10, Figure 4 of reference 11). In this 
way, spectral constructs were generated from the changes in the spectra of the 
nuclear region, including increases in the characteristic A form of DNA peak at 
807 cm-1 and the B form peak at 833 cm-1 and a change in the C-H deformation 
at 1449 cm-1 (Figure 4.1A) and in the cytoplasmic region, containing the 
following peak changes or shifts; a change in the amide 1 band at ~1661 cm-1, a 
decrease in the C-C stretch intensity at ~939 cm-1 and an increase in the 
tryptophan peak at 731 cm-1 (Figure 4.1B). The relative intensities of the peaks in 
each construct were derived from the experimental difference spectra at a cis-
platin exposure dose of 3µM10 and were normalised for concentration (Figure 
4.1A) and a loss of viability at that concentration of 0.52 10 (Figure 4.1B). 
Different weightings of these spectral constructs (termed hereafter the 
Concentration and Viability construct respectively) were then added to a control 
dataset as described in the following section.    
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Figure 4.1: Spectral Constructs based on the normalised difference spectra 
between control and exposed nucleus (A) 10, and cytoplasm 11 (B). Selected Raman 
peaks were used to avoid over complexity in the simulated data; (A) the A form 
peak of DNA at 807 cm-1 and the B form peak at 833 cm-1 and the C-H 
deformation at 1449 cm-1 (B) the amide 1 band at ~1661 cm-1, the C-C stretch 
intensity at ~939 cm-1 and the tryptophan peak at 731 cm-1.  
 
4.3.4 Simulated data  
Simulated datasets were generated in the following manner. A control 
dataset containing 25 spectra acquired from the nucleus of non-cis-platin exposed 
(control) cells was selected from Nawaz et al  1 (Figure 4.2). Notably, this real 
experimental dataset contains instrumental noise and sample variability. To this 
dataset, weighted contributions of the Concentration construct shown in Figure 
4.1A, based on the experimentally observed difference spectra of the nuclear 
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region, were added, over the Lethal Concentration range 0.05 µM - 50µM used 
in the original study, based on a direct weighting of the spectral construct by the 
range of concentrations (Table 4.1).  Initially, only the concentration dependent 
weighted constructs were added to the control, to produce Dataset 1.  
 
 
Figure 4.2: Control dataset taken from Nawaz et al.1; 25 control spectra taken 
from the nucleus of cells not exposed to cis-platin. Spectra have been baseline 
corrected and vector normalised. The inherent spectral variability in the data is 
representative of real experimental conditions. These spectra were then used in 
the construction of 3 simulated datasets, each containing 8 different dose/viability 
points with systematically introduced variation of the spectral constructs shown 
in figure 4.1.    
 
As the MTT assay is expressed in viability compared to control (0.845 
being maximum (Vmax) and 0.135 being minimum values of fit to the 
experimentally observed viability over the concentration range10), the spectral 
construct of Figure 4.1B, derived from the experimentally observed differences 
in the cytoplasmic region, was similarly weighted by the (Vmax – MTT) endpoints 
in Table 4.1 and also added to Dataset 1. Each spectral construct was therefore 
added following a linear trend based on concentration (Figure 4.1A) plus a linear 
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trend based on MTT response (Figure 4.1B). The MTT endpoint data are, 
however, nonlinearly related to the concentration, in a sigmoidal fashion typical 
of cytotoxic responses, as shown in Nawaz et al1,2. The resultant dataset therefore 
contains 25 spectra for each of 8 dose points (including control) which 
incorporate spectral variations, systematically dependent on both the exposure 
dose and the measured cytological response. For simplicity, this is referred to as 
Dataset 2. 
It is noted that the spectral construct of Figure 4.1B is derived from 
exposure dose dependent, experimentally observed, spectral changes in the 
cytoplasmic region. No direct biological significance is inferred by the weighted 
addition of this spectral construct to the dataset derived from the nuclear regions. 
However, the addition serves to provide an independently variable perturbation 
to the dataset, which may serve to mimic a cytological effect of the direct action 
of the drug in the nucleus.  
To probe the sensitivity of the methodology, the experimental range for 
cis-platin (Lethal Concentration, in table 4.1) has been extended (Sub lethal 
Concentration in table 4.1) to represent non-lethal doses of the drug. The MTT 
values have also been extrapolated according to the original fit of the Hill 
equation10 to reflect these changes in concentration (Sub-lethal MTT in table 4.1). 
The corresponding simulated dataset will be referred to as Dataset 3. A dataset 
was also constructed which consisted solely of control spectra. This Control 
dataset did not contain any systematically introduced spectral variations and was 
used to establish a baseline regression endpoint for both Lethal Concentration and 
Lethal MTT.   
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Table 4.1: The weightings of the spectral constructs added to the control data. 
The Lethal Concentration and Lethal MTT ranges are derived from the actual 
experiment data of references 1,2. Lethal MTT represents the values obtained 
when the experimental MTT value is subtracted from Vmax. The Sub-lethal 
Concentrations extend the concentration range and are representative of sub-
lethal doses of cis-platin, for which sub-lethal MTT values are derived from the 
extrapolated fit of the Hill equation in Reference 1.  
  
4.4 Results 
4.4.1 Concentration Simulated data 
The PLSR method aims to establish a model that relates the variations of the 
spectral data to a series of relevant targets. In this case, the spectral data is a series 
of simulated datasets which are based on known introduced perturbations based 
on cis-platin-cellular interactions as described in the previous sections. 
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Figure 4.3. PLSR modelling against Lethal Concentration for Dataset 1. Top 
panel shows the calibration performance and test dataset (RMSEC 0.49673, R2 
0.99948). Bottom panel shows the performance of the model for the test dataset 
(RMSEP 0.52389, R2 0.99953). Data was split in a ratio of 60:40 calibration and 
test respectively.  
 
Regression of Dataset 1 against the Lethal Concentration range (table 4.1) yielded 
the model shown in figure 4.3. The data were split, 60:40, to create calibration 
and test sets to build the model. 60% of the data was used to calibrate the model 
and 40% of the data was then used to assess the performance of the model in 
predicting the expected target with unseen data. Leave-one out cross validation 
with the calibration set was used to determine the optimal model complexity for 
use in testing (Meade et al., 2010)27. This process was performed with 
randomization of the data matrix and splitting of the data to prevent data bias 
(Varmuza and Filzmoser, 2009)28. Control of over fitting was achieved using a 
procedure previously described by Martens and Naes29. The procedure involves 
selection of the optimal number of latent variables (LV) to retain within the PLSR 
model via cross-validation with the calibration data set. The optimal number of 
LV's was then selected on the basis of the number which provided the lowest root 
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mean squared error after cross validation. This is illustrated in Supplementary 
Material figure S4.1A and B, which show plots of the RMSECV and RMSEP for 
the first 10 LV’s for the regression of Dataset 1 against Lethal Concentration 1, 
and thus the optimum number of LV’s was selected as 10. The calibration and 
test set had RMSEC=0.49673, RMSEP=0.52389 and R2 values of 0.99948 and 
0.99953 respectively, indicating a good linear fit of the model.  
 As the regression co-efficient (RC) are descriptors of the spectral features 
which are used to build the model, we also aimed to assess the accuracy with 
which the algorithm can faithfully extract the known spectral perturbations 
introduced in the dataset. For regression of Dataset 1 against Lethal 
Concentration, we expect that the spectrum of the RC will be comprised of the 
Concentration construct which has been added based on the Lethal Concentration 
range (Figure 4.1A).  
 In figure 4.4, a direct comparison between the RC of regression of Dataset 
1 against the Lethal Concentration range and the concentration spectral construct 
is shown. The spectrum of the RC is dominated by the peaks of the systematically 
added spectral construct, at 807cm-1, 833cm-1 , which correspond to A and B form 
DNA10 and the C-H deformation at 1449cm-1 (solid line figure 4.4 bottom panel). 
This verifies that the simulated changes are the major contributors to the PLSR 
model construction.  
  
 89 
 
Figure 4.4: Plot of the regression co-efficient following PLSR of Dataset 1 
against Lethal Concentration. The Concentration construct (dashed line) is 
shown in the top panel for comparison with the RC’s in the bottom panel. The 
solid line (bottom panel) shows the regression co-efficient following regression 
of Dataset 1 against Lethal Concentration. The dotted line shows a plot of the 
regression co-efficient following regression of a dataset consisting of just control 
spectra against Lethal Concentration, in effect showing the baseline regression 
co-efficient when no introduced spectral perturbation (not including 
sample/instrumental variations) is present. The Control RC has been offset and 
multiplied by a factor of 10 for clarity. 
 
However, it should be noted that the RC spectrum in figure 4.4 also contains other 
peaks which are not present in the spectral construct and so should not show a 
systematic variation with concentration. By regression of just the control data 
(with no spectral perturbations) against the Y target (Lethal Concentration) it was 
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possible to establish a Control RC, as shown by the dotted line (bottom panel) in 
figure 4.4 (offset and multiplied by a factor of 10 for clarity). The control RC 
spectrum shows a high degree of similarity with the original cellular spectra 
(Figure 4.2) and thus derives from the inherent variability in the experimental 
measurement. Close examination of the RC for the Dataset 1 regression reveals 
that some of the peaks in the Control RC are also present.  
The PLSR modelling process was repeated for Dataset 2, which included 
the combined perturbations of the Concentration construct of Figure 4.1A, 
linearly weighted according to Lethal Concentration of Table 4.1, and the MTT 
Construct of Figure 4.1B, linearly weighted according to Lethal MTT of Table 
4.1. A similar performance of model calibration and test were achieved, with 
RMSEC=0.4981, RMSEP=0.53505 and R2 values of 0.99947 and 0.99952 
respectively, again indicating a good linear fit of the model (Figure S4.2). The 
spectrum of RC again faithfully reproduced the Concentration Construct of 
Figure 4.1A, on a background which matches well the Control RC spectrum 
(Figure S4.3). 
4.4.2 MTT Simulated Data 
Dataset 2 also contains systematic perturbations which have been weighted 
according to the viability as measured using the MTT assay, and it is of critical 
interest whether these spectral variations can be independently extracted using 
PLSR, as suggested by Nawaz et al.10. Regression of Dataset 2 against Lethal 
MTT (table 4.1) yielded the model shown in figure 4.5. As for the concentration 
dependent model, the data are split according to 60% calibration and 40% test 
data. The calibration and test set had RMSEC=0.10158, RMSEP=0.12087 and R2 
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values of 0.91928 and 0.89793 respectively. Based on these values, it can be seen 
that, while the model has fitted the data, it does not provide as good prediction as 
shown for concentration (figure 4.3). This is also reflected by the lower R2 values, 
considering that the accuracy of the linear fit is measured by how close the value 
is to 1. A possible explanation for this is the lower magnitude and range of 
weightings of spectral construct added corresponding to the MTT response (Table 
4.1, Lethal MTT).  
 
Figure 4.5: PLSR modelling of Dataset 2 against the Lethal MTT target. Top 
panel shows the calibration performance and test dataset (RMSEC 0.10158, R2 
0.91928). Bottom panel shows the performance of the model for the test dataset 
(RMSEP 0.12087, R2 0.89793). Data has been split in a ratio of 60:40 calibration 
and test respectively. 
 
 Inspection of the MTT RC in Figure 4.6 shows that the peaks of the 
systematically added Viability construct (Figure 4.6, dashed line, top panel), the 
amide 1 band at ~1661 cm-1, the C-C stretch intensity at ~939 cm-1 and the 
tryptophan peak at 731 cm-1, are faithfully reproduced and dominate the MTT RC 
(Figure 4.6, solid line, bottom panel).  
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Figure 4.6: Plot of the regression co-efficient following PLSR modelling against 
MTT response. The Viability construct (dashed line) is shown in the top panel for 
comparison with the RC’s in the bottom panel.  The solid line shows the 
regression co-efficient following regression against Lethal MTT and Dataset 2 
(bottom panel). The dotted line (bottom panel) shows a plot of the regression co-
efficient following regression of a dataset consisting of just control spectra 
against Lethal MTT, in effect showing the baseline regression co-efficient when 
no introduced spectral perturbation (not including sample/instrumental 
variations) is present. The Control RC is offset and multiplied by a factor of 10 
for clarity.    
 
 The baseline sensitivity is evaluated by regressing the control dataset 
against the Lethal MTT target, yielding the Control RC of Figure 4.6 (bottom 
panel, dotted line). The resultant RC spectrum has been offset and multiplied by 
a factor of 10, for clarity. As in the case for regression against Lethal 
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Concentration targets, the Control RC resembles the cellular spectra of figure 4.2, 
indicating that the baseline variation is limited by the variations in the original 
spectral measurement. 
4.4.3 Quantitative evaluation of regression co-efficient 
In an attempt to evaluate the quantitative nature of the regression co-efficient, a 
method was devised which looked at varying the number of data-points used to 
build the PLSR model. For the analysis of the spectral variations of Dataset 1, 
based on variations of the Concentration construct of figure 4.1A weighted 
according to Lethal Concentration (Table 4.1), multiple regressions were 
conducted (models not shown). Each model was constructed by increasing the 
number of data points, C+1 being the first data set used, consisting of the control 
dataset (Fig 4.2) and the 0.05 µM data-point of the Lethal Concentration range 
(Table 4.1). The data set was then successively extended by 1 data-point, such 
that C+2 consists of control, 0.05 µM and 0.5 µM, and so on, until all data points 
in the Lethal Concentration were included.  
For all models, the spectrum of the RC displayed a combination of the 
Concentration construct of Figure 4.1A and the Control RC of Figure 4.4, and, as 
expected, regression over the full range reproduced the RC spectrum of Figure 
4.4. Notably, as shown in Figure 4.7, the peaks of the Concentration construct 
increase linearly as the range of the regression is increased and reach a saturation 
value above ~ C+4. Extension of the model to 1000µM results in no further 
significant increase of these maximum peak intensities (data not shown). The A-
form DNA peak at 807cm-1 reaches a maximum value of 18.46. Although this 
does not quantitatively equate to the corresponding peak value of the Control 
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construct of Figure 4.1A, the relative magnitudes of the respective peaks is 
consistent with those of the original Concentration construct, and notably the 
relative contribution of the Control RC is reduced with increasing range. 
 
Figure 4.7: Evolution of the peaks of Construction construct in PLSR models of 
increasing range for Dataset 1. 
 
A similar analysis was conducted for the PLSR of Dataset 2 against the 
Lethal Concentration range. Figure 4.8 shows a plot of the extracted RCs for all 
successive regressions. As expected, C+7 reproduces the Lethal Concentration 
RC of Figure 4.4, and extracts the expected introduced spectral construct (Figure 
4.1 A). However, notably for all other regressions, C+1 to C+6, the presence of 
peaks which are not explicitly dependant on Lethal Concentration are observed. 
In addition to those of the Control RC, peaks of the MTT construct (Figure 4.1B) 
are evident in the RCs of the regressions over the incomplete concentration range. 
A similar phenomenon can be seen in the equivalent sequential modelling of the 
MTT data of Dataset 2 (Figure S4.4 and S4.5).  
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Figure 4.8. A plot of regression co-efficient following multiple regression against 
concentration with increasing data points. I.e. C+1 represents a dataset 
consisting of the control dataset and the data point at 0.05 µM. This then 
increases C+n until all data points in the dataset have been evaluated.   
 
 Figure 4.9 shows a plot of selected RC peak intensities associated with 
the spectral construct relating to concentration following successive rounds of 
regression as described above, namely the A form peak of DNA at 807 cm-1 and 
the B form peak at 833 cm-1, which are associated with the physical changes 
associated with cis-platin-cellular interaction2. In fact the evolution of the peaks 
is observed to be identical to that observed for Dataset 1, shown in Figure 4.7, 
and although the plot of Figure 4.9 is in a linear/logarithmic format, it can be seen 
that the predicted relative intensities again increase linearly initially, before 
reaching a point of saturation at, or above, the dataset C+4, and further addition 
of data-points makes no difference (data not shown) to the quantitative prediction 
of the features.  
Also shown in Figure 4.9 is the dependence of the peak of the Viability 
construct at 731cm-1, (for example) which “bleeds through” in the regression of 
Dataset 2 against the incomplete concentration range. This bleed through occurs 
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for all peaks of the MTT Construct. The contribution of the peaks of the Viability 
Construct follows a trend of the derivative of the viability curve, indicating that 
it is the rate of change of the contributed spectral variations which governs the 
contribution to the RC. Notably, when the full Lethal Concentration range is 
included in the model, at the extremes of which the change in viability has 
reduced to the minimum value, the bleed through of the MTT construct is 
minimal, and the Concentration Construct of Figure 4.1A is faithfully extracted, 
albeit with an underlying background as a result of the inherent spectral 
variability. 
 
 
Figure 4.9. Plot of peak intensities vs. concentration of regression co-efficients 
for the A form peak of DNA at 807 cm-1 and the B form peak at 833 cm-1 of the 
Concentration Construct (Figure 4.1A). Also plotted is the contribution of the  
tryptophan peak at 731cm-1, a key feature of the Viability Construct (Figure 4.1B)  
 
A similar PLSRA of the contributions of the Viability construct to Dataset 
2 reveals similar bleed through and more complex evolution of the features 
contributing to the spectrum of the RC (Supplementary Material Figures S4.4 and 
S4.5). The bleed through of the features of the spectral constructs shown in 
Figures 4.8 and 4.9 is a clear demonstration that it is not trivial to independently 
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extract the contributions of the two constructs over the lethal concentration range, 
as speculated by Nawaz et al.10. However, over concentration ranges in which the 
viability does not change significantly, the bleed through is minimal, and the 
concentration dependent spectral changes can be independently extracted. Thus, 
it should be possible to determine the direct chemical interactions of an external 
agent in the sub-lethal range.  
Figure S4.6 shows the calibration and test performance of the PLSR of 
Dataset 3 versus the sub-lethal concentration range of Table 4.1. The model yields 
RMSEC and RMSEP values of 0.143 and 0.19392, respectively, with R2 values 
of 0.38916 and -0.24063, accuracies considerably less that those of the equivalent 
model in the Lethal Concentration range. Notably, the RC spectrum is a faithful 
extraction of the pure Concentration construct of Figure 4.1 A, as shown in Figure 
S4.7. Little or no bleed through of features associated with the Viability construct 
is apparent (although still present in minimal quantities) although this is not 
surprising as, with little or no change in viability, the contributions of the 
Viability construct to Dataset 3 are minimal.  
4.5 Discussion 
Given the drive for a reduction in the use of animal models for evaluating toxicity, 
screening of drugs and even cosmetics, due to regulatory developments in both 
the EU and US (EU Directive-2010/63/EU and US Public Law 106-545, 2010, 
106th Congress)30–32  generally based on the 3 R’s of Russell and Burch30 to 
replace, reduce and refine the use of animals used for scientific purposes, there is 
increased emphasis on the development of reliable and rapid in-vitro screening 
methodologies. This includes more representative culture models which better 
 98 
mimic the in-vivo environment as well as more rapid, cost efficient, high content, 
and ideally label free screening technologies. It is crucial, however, that these 
models and technologies are well validated against established gold standards33,34.  
Raman spectra, in principle, contain high content information about the 
biochemical make up of the sample, and changes to it, related to pathology or an 
external agent. Raman spectra contain numerous peaks which vary dependently 
and independently of each other. Crucially, for real applications and particularly 
in the instance of drug interactions, it is difficult to tell whether these differences 
are inherently based on cell to cell variability or whether they are dependent on 
the primary action of the drug (i.e. the direct chemical effects) or the secondary 
effects the drug has on the cell (i.e. the response of the cell to said drug). 
In this study, simulated datasets were used to evaluate the capability of 
PLSR to extract known and systematic spectral variation from a control dataset, 
which contained intrinsic experimental variability. The spectral variations 
introduced varied linearly with the applied drug dose and also with the measured 
cell population response, as measured by a standard cytotoxicity assay. Notably, 
however, the two spectral variations are not completely independent, as the 
viability response is sigmoidal dependent on the applied dose. 
In the case where only a concentration dependent systematic variation in 
the spectra is introduced, the PLSR model provides an accurate predictive 
response tool, the regression co-efficient of which are based on the systematic 
variation which has been introduced to the dataset, linearly dependent on the 
targets. The model shows high sensitivity, and the limits of detection are 
determined only by the intrinsic variability of the experimental method, as 
determined by the PLSR of the Control spectral dataset. This limit can be 
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improved by optimising sample preparation and measurement protocols. In 
principle, such a PLSR model can predict the response of a drug dose in a cell 
population, or determine an unknown drug dose from a measured spectral 
response. 
However, the spectral changes which result from the interaction and 
action of a drug within a cell are manifold, and it is of interest to differentiate the 
spectral signatures of the direct interaction from the subsequent cellular response. 
Notably, this study demonstrates that, although PLSR predictive models based on 
regression of the combined dataset, including all spectral responses, against the 
target of concentration range produce a similarly accurate, linear predictive 
model, the contributing RCs are only derived exclusively from the introduced 
concentration dependent variations in ranges where all other spectral variations 
are limited. For example, as shown in Figures 4.8 and 4.9, regression over the 
limited range of C+4 produces a model which is based on RCs which includes 
contributions derived from the direct effect of the interaction of the drug within 
the cell (Concentration construct), as well as the resultant cytological response 
(Viability construct). Thus, care should be taken in interpreting the spectral 
features which contribute to such regressions to elucidate the underlying 
mechanisms. 
Nevertheless, in sub-lethal regions, the direct effects of the drug 
interaction can confidently be investigated employing such a PLSR analysis of 
Raman spectral data, independent of the cytological responses, and these are 
easily discernible above the intrinsic variability of the control. Although this 
seems a trivial conclusion, such rapid, label free analysis could prove invaluable 
in screening of, for example, the mechanisms and efficacy of drug interactions, 
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evaluating drug uptake and receptor binding25 or nanoparticle uptake and 
trafficking in regions where cytoxicity assays are insensitive. 
The use of a parallel cytotoxic assay such as MTT serves as a range 
finding test to establish the IC50, but also provides vital information about the sub-
lethal doses and maximum responses. It also provides a target for regression of 
the data in the regions of toxicity. Thus, the subsequent cytological effects can be 
differentiated from the direct chemical effects of the agent and extracted from the 
overall spectral response in the dose range where the viability is impacted, and 
the cellular response can be independently mapped spectroscopically, as a 
function of dose and time. Notably, the model described here, which includes a 
single spectral construct to represent the cellular response is very simplistic, as 
the response is a cascade of many responses, depending on the mechanism of 
interaction35. Nevertheless, the analysis presented here demonstrates that the 
spectral fingerprints of the direct mechanisms of interaction and the subsequent 
cellular responses can be independently extracted from the dose dependent 
spectral data, and thus, ultimately with improved screening sensitivities and 
speeds, Raman spectroscopy could be employed to monitor in quasi real time, in 
a label free manner, the efficacy and mode of action of, for example 
chemotherapeutic agents and other exogenous agents, laying the basis for 
improved quantitative structure activity relationships to guide drug development 
or chemical regulation strategies.  
4.6 Conclusions 
This study demonstrates the reliability and also limitations of PLSR as a method 
for predictive modelling and analysis of spectroscopic signatures of cellular 
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responses to exogenous agents such as radiation, chemotherapeutic agents or 
toxins. The spectroscopic profiles at any dose/time point can derive from a 
complex mixture of direct interactions within the cell and a cascade of subsequent 
cellular response. The analysis demonstrates that care should be taken in choosing 
the response range and also highlights the importance of parallel cytological 
assays in guiding the modelling and analysis. Correct choice of range can help 
differentiate between the signatures of direct interactions, which are dominant at 
sub-lethal doses and those of the subsequent cellular response which evolve with 
increasing dose. 
The study also demonstrates the importance of simulated datasets in 
exploring the potential as well as the limits of the analytical techniques. Notably, 
the use of real experimental data which contains sample variability and 
instrumental response factors as a basis of the simulated dataset helps to visualise 
the lower limits of sensitivity.  
The results indicate that Raman spectroscopic screening combined with 
such regression models and feature selection techniques, in parallel with 
conventional cytotoxicity assays, can be used to screen for the efficacy of drug 
interactions and can contribute to understanding the mechanisms of interaction. 
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4.9 Supplemental Material: 
Multivariate statistical methodologies applied in biomedical Raman 
spectroscopy: Assessing the validity of partial least squares regression using 
simulated model datasets.   
 
Mark E. Keating1,2*, Haq Nawaz3 , Franck Bonnier1,4 and Hugh J. Byrne1   
1FOCAS Research Institute, Dublin Institute of Technology, Kevin Street, Dublin 
8, Ireland. 
2School of Physics, Dublin Institute of Technology, Kevin Street, Dublin 8 
Ireland. 
3National Institute for Biotechnology and Genetic Engineering (NIBGE), 
P.O.Box 577, Jhang Road Faisalabad, Pakistan. 
4Faculty of Pharmacy, EA 6295 – NM/NP, Université François-Rabelais de 
Tours, 60 rue du Plat D'Etain, 37020 Tours Cedex 1, France 
 
 
 
Figure S4.1: RMSECV and RMSEP for the first 10 LV’s for the regression of 
Dataset 1 against Lethal Concentration 1 
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Figure S4.2: PLSR modelling of Dataset 2 with the Lethal Concentration range 
as taregt. Top panel shows the calibration performance and test dataset (RMSEC 
0.4981, R2 0.99947). Bottom panel shows the performance of the model for the 
test dataset (RMSEP 0.53505, R2 0.99952). Data was split in a ratio of 60:40 
calibration and test respectively.  
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Figure S4.3: Plot of the regression co-efficient following PLSR modelling of 
Dataset 2 against Lethal Concentration. The concentration spectral construct 
(dashed line) is shown in the top panel for comparison with the RC’s in the bottom 
panel. The dashed line (bottom panel) shows the spectrum of regression co-
efficients following regression of Dataset 2 against Lethal Concentration 1. The 
solid line shows a plot of the regression co-efficient following regression of a 
dataset consisting of just control spectra against Lethal Concentration, in effect 
showing the baseline regression co-efficient when no introduced spectral 
perturbation (not including sample/instrumental variations) is present. The 
Control RC has been multiplied by a factor of 10 and offset for clarity. 
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Figure S4.4. A plot of regression co-efficients following multiple regression of 
Dataset 2 against Lethal MTT with increasing data points. I.e. C+1 represents a 
dataset consisting of the control dataset and the data point at 0.05 µM. This then 
increases C+n until all data points in the dataset have been included.   
 
 
Figure S4.5 Plot of RC peak intensities for regression of Dataset 2 against Lethal 
MTT; C-C stretch intensity at ~939 cm-1, the amide 1 band at ~1661 cm-1 and the 
tryptophan peak at 731 cm-1 of the Viability Construct (Figure 1B). 
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Figure S4.6. PLSR modelling of Dataset 3 with the Sub-lethal Concentration 
range as target. Top panel shows the calibration performance and test dataset 
(RMSEC 0.143, R2 0.38916). Bottom panel shows the performance of the model 
for the test dataset (RMSEP 0.19392, R2 -0.24063). Data was split in a ratio of 
60:40 calibration and test respectively. 
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Figure S4.7. Plot of the regression co-efficients following PLSR of Dataset 3 
against Sub-lethal Concentration. The concentration spectral construct (dashed 
line) is shown in the top panel for comparison with the RC’s in the bottom panel.  
The solid line shows the regression co-efficient following regression against sub-
lethal concentration and Dataset 3 (bottom panel). The dotted line (bottom panel) 
shows a plot of the regression co-efficient following regression of a dataset 
consisting of just control spectra against sub-lethal concentration, in effect 
showing the baseline regression co-efficient when no introduced spectral 
perturbation (not including sample/instrumental variations) is present. The 
Control RC is offset and multiplied by a factor of 100 for clarity.    
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Chapter 5 Seeded Principal Component Analysis for 
biochemical screening using vibrational spectroscopy 
5.1 Abstract: 
Seeded Principal Component Analysis (SePCA) is introduced as a novel 
multivariate analysis variant to address some of the limitations of the application 
of PCA in bio-spectroscopy in systematically varying datasets. Using simulated 
data based on experimental spectra of in-vitro exposure to varying doses of the 
chemotherapeutic agent, cis-platin, standard and SePCA are compared, firstly 
based on their ability to differentiate the responses to different exposure doses, 
and secondly to assess the accuracy of the loadings that are used to describe the 
systematic variations of biochemistry underlying the differentiation. Further 
insights are also garnered on the use of 1st and 2nd derivative spectra and the 
impact this mathematical transformation has on the ability of the algorithm to 
separate and describe the spectral origin of differentiation of spectral datasets. 
The implications of this novel variant of PCA are discussed in the context of 
screening for drug efficacy in-vitro as well as biomedical classification for disease 
diagnostics. 
5.2 Introduction 
Raman spectroscopy is a branch of vibrational spectroscopy which allows for a 
sample to be characterised based on its inherent chemical nature in a label free 
manner. The resulting spectra can then be used to classify a host of materials from 
organic to inorganic compounds. Recently, vibrational spectroscopies such as IR 
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and Raman have gained momentum in a biomedical context, with a guiding focus 
of translating these technologies into the clinical environment1. 
 Both histopathological and cytological studies have been routinely carried 
out using both IR and Raman spectroscopic analysis and have shown significant 
success in the laboratory at diagnosing disease states with high sensitivity and 
specificity, based on the inherent biochemical state of the sample as opposed to 
the morphology2. Further studies have investigated other disease states such as 
atherosclerosis3, liver cancer and disease4–6,lung cancer7, colon cancer8, blood 
borne illnesses such as malaria and others9,10, as well as investigations in 
dermatology11. Additionally, bio-fluid analysis has also been developed in 
conjunction with IR and Raman spectroscopy as a potential alternative to current 
gold standard practices12. In-vivo and ex-vivo Raman spectroscopy has also been 
demonstrated in a number of studies, including the investigation of brain13, 
cervical14 and oesophageal15 pathologies16   
 Vibrational spectroscopy has also seen usage in other medical contexts 
such as Nanomedicine17, in which Raman and its variants allow for label free 
characterisation of nanomaterials in cells as well as tissues and live animal 
studies. Pharmacological characterisation in-vitro has also been demonstrated 
with a number of drugs classified using Raman spectroscopy as a tool to monitor 
drug behaviour in a cellular environment18–22.  
 Crucially, there are a number of caveats associated with this technique 
and all play a role in the end goal of accurate label free sample characterisation. 
These range from correct sample preparation in the laboratory, precise sampling 
by the spectrometer (incorporating sample location as well as instrument 
precision and reproducibility), through to the correct spectral pre-processing, 
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including baseline correction, smoothing, normalisation…etc. Finally, the correct 
usage and development of novel multivariate statistical methodologies for 
analysis and interpretation of the biochemistry underlying the spectral signatures 
is important for validity, accuracy and interpretability1,23,24. 
 In previous publications by Keating et al25,26, simulated datasets were used to 
probe the intricacies of Partial Least Squares Regression (PLSR) and a novel 
multivariate approach, termed spectral cross correlation analysis (SCCA) and its 
use in biomedical Raman spectroscopy. In brief, the validity of the method to 
extract and differentiate the spectral signatures of the direct action of and 
subsequent metabolic response to chemotherapeutic agents and nanoparticles 
(respectively) in cells in-vitro, was demonstrated. The use of simulated datasets, 
based on real experimental data, enabled verification of the validity of the 
techniques and estimation of the limits of sensitivity, while also identifying 
potential limitations of the techniques, highlighting the importance of 
understanding the intricacies of multivariate statistical methodologies applied in 
vibrational spectroscopy. 
 In a study by Bonnier and Byrne in 2011, principal component analysis 
(PCA) was investigated and its use and interpretability in spectral applications 
was elucidated27. While this method is commonly applied in biomedical 
spectroscopy as a means of differentiating and classifying spectral datasets, the 
biochemical reasoning behind separation and its dependence on the loadings can 
often be misinterpreted. This publication aimed to shed light on some of the 
possible pit falls in interpreting spectral separation using both real and simulated 
data. 
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 Following on from this work, as well as the validation of the PLSR 
technique by Keating et al25 , the current study aims to further probe the PCA 
algorithm using simulated data, and in particular to explore its use to analyse 
systematic variations in spectral responses as a result of quasi-continuous 
variations in exposure of cell populations to external stimuli. Some of the 
deficiencies of the method are highlighted and investigated, looking at 
continuously varying data and loading interpretability in a spectral context that of 
systematic variations due to variable doses of chemotherapeutic agents in cells, 
in-vitro. A novel variant protocol for carrying out PCA, termed seeded PCA 
(SePCA), has been developed to overcome some of the deficiencies in the current 
usage of the algorithm in spectroscopy.      
5.3 Methods  
5.3.1 Simulated data  
The generation of the simulated data used has been described in detail 
elsewhere25. A modified version of the protocol is described here to tailor the 
dataset for the study of PCA. The full details of the culture and experimental 
conditions can also be found elsewhere18 In brief, human lung adenocarcinoma 
(A549) cells were routinely cultured at 37 °C, 5 % CO2 in DMEM F12 
supplemented with 10% FBS, 1% pen/strep and 2mM l-glutamine. Cells were 
cultured until 70-80% confluency and plated on quartz substrates for Raman 
spectroscopy. Twenty five control spectra were acquired in the previous study by 
Nawaz et al18. Figure 5.1 shows the control spectra used. These consist of spectra 
acquired from the nuclei of A549 human lung adenocarcinoma cells in-vitro, with 
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no external agent added. In parallel, a standard MTT cytotoxicity assay was 
carried out to establish the dose dependence of the in-vitro viability.  
 
 
 
Figure 5.1. Control dataset taken from Nawaz et al18. 25 control spectra taken 
from the nucleus of cells not exposed to cis-platin. Spectra have been baseline 
corrected and vector normalised. The inherent spectral variability in the data is 
representative of real experimental conditions. 
 
Spectral constructs, shown in figure 5.2, were generated from the mean 
difference between spectra from concentration dependant changes in the nucleus 
and the control, as well as spectra from the cytoplasm and the control, which 
correspond to the MTT cytotoxic response as described in the publications by 
Nawaz et al. 18,19. In these publications, the exposure of cells to cis-platin was 
carried out over the concentration range from 0.05µM-50µM, including the mean 
inhibitory concentration, IC50 of ~ 3µM, as identified using the MTT cytotoxicity 
assay. This dose range in conjunction with the MTT response was then used to 
construct simulated data.   In this way, spectral constructs were generated from 
the changes in the spectra of the nuclear region, including increases in the 
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characteristic A form of DNA peak at 807 cm-1 and the B form peak at 833 cm-1 
and a change in the C-H deformation at 1449 cm-1 (Figure 5.2A) and in the 
cytoplasmic region, containing the following peak changes or shifts; a change in 
the amide 1 band at ~1661 cm-1, a decrease in the C-C stretch intensity at ~939 
cm-1 and an increase in the tryptophan peak at 731 cm-1 (Figure 5.1B).  
These were then used to introduce systematically variable, known 
perturbations into the control dataset, in such a way as to generate a number of 
different datasets based on the original experimental results obtained by Nawaz 
et al18. to investigate both the standard PCA algorithm and the novel seeded 
variant.  
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Figure 5.2: Spectral Constructs based on the normalised difference spectra 
between control and exposed nucleus (A) and cytoplasm (B) of Nawaz et al. 
(2010). Selected Raman peaks were used to avoid over complexity in the 
simulated data; (A) the A form peak of DNA at 807 cm-1 and the B form peak at 
833 cm-1 and the C-H deformation at 1449 cm-1 (B) the amide 1 band at ~1661 
cm-1, the C-C stretch intensity at ~939 cm-1 and the tryptophan peak at 731 cm-1.  
 
The perturbation of construct 1 (Figure 5.2 (A)) is used to represent the 
systematic spectral evolution due to the direct interaction of the chemotherapeutic 
agent in the nucleus, while construct 2 (Figure 5.2 (B)) is used to represent the 
systematic variations in viability of the cell population, as measured by the MTT 
assay. The weightings listed in table 5.1 show the magnitude of the changes added 
to the control dataset of figure 5.1. Three datasets were generated from these sets 
of values, one of which consists of the control (25 spectra) plus the maximal MTT 
(25 spectra) value of table 5.1 (Dataset 1),  
 
Dataset 1: (Control), (Control + WMaxMTT)  
 
where WMaxMTT indicates the addition of the maximally weighted MTT spectral 
construct in table 5.1 i.e. 0.66*MTT spectral construct (Construct 2).  
The second dataset (Dataset 2) contains the control and the maximally 
weighted values for both the concentration (Construct 1) and MTT (Construct 2) 
constructs. Each of the weighted constructs, WMaxConc and WMaxMTT, are added 
to the control dataset separately in the first instance with the purpose of creating 
a simulated system to probe the ability of standard and seeded PCA to accurately 
separate the three groups, each containing 25 spectra, which make up the dataset.  
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Dataset 2: (Control), (Control + WMaxMTT), (Control + WMaxConc )   
 
A further, more complex version of the dataset was constructed using all 
the weightings in table 5.1, generating a dataset with simultaneous, continuously 
varying concentration and continuously varying MTT constructs, the final data 
matrix having the format of: 7x25 weighted spectra plus 25 controls. 
 
Dataset 3: (Control), (Control +WMTTn+Conc.n +WMTT.n+1+Conc.n+1……)  
 
Dataset 3 thus simulates the spectral changes observed experimentally as 
a result of exposure of A549 cells in-vitro to cis-platin of continuously varying 
concentration. 
Approximate partial first and second derivative spectra were calculated 
using the ‘diff’ function in Matlab (Mathworks, USA)), with seeded and standard 
PCA carried out on selected datasets (1-3) to highlight the improvements made 
possible by this mathematical transformation. 
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Table 5.1 the weightings of the spectral constructs added to the control data. The 
Concentration and MTT ranges are derived from the actual experiment data of 
references18,19 MTT represents the values obtained when the experimental MTT 
value is subtracted from the maximum viability 
5.3.2 PCA 
PCA is a method which aims to reduce the dimensionality of the data to describe 
the variation present in a dataset, whereby the first principal component is a 
description of the maximum variance present in the dataset, the second describes 
the second most variance…etc. The principal component scores can then be 
described by the loading vector, which is a representation of this variance. In a 
Raman spectroscopy context, the scores represent values which correspond to a 
loading spectrum which contains peaks, both positive and negative, which explain 
the spectral variation in the dataset17.This tool can be quite useful for classifying 
spectra into groups e.g. diseased and non-diseased14. It has also been used to 
reconstruct images28,29, i.e. a variance plot based on the loadings plot. However, 
as these loadings plots may often contain a number of spectral features 
corresponding to different cellular biochemistry, interpretation can be difficult 
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and it is quite possible to misinterpret. Bonnier et al. have shown that pairwise 
PCA of clusters identified by KMCA can provide a clearer picture of the specific 
biochemical differences between region30. All spectra were centred using a single 
value decomposition (SVD) algorithm for analysis using the following function. 
All analysis was done using the ‘pca’ function in  Matlab (The Mathworks Inc.).    
5.3.3. Seeded PCA 
Considering that PCA is sensitive to the relative scaling of the original variables, 
it is postulated that seeding the examined dataset with the known perturbation 
might have the effect of increasing the accuracy and or sensitivity of the standard 
PCA algorithm. In the case of interest, the spectral signature of the nuclear 
binding of the chemotherapeutic agent may be known, and thus the 
experimentally observed spectral changes may be data-mined for this signature. 
This is done by the addition of the pure spectral constructs of Figure 5.2 to the 
Datasets of control and perturbed control spectra described in Section 5.3.1.  
To optimise for seeding using an optimised seeded weight (OSW), it is 
necessary to understand how the variance changes as the magnitude of the 
spectral construct added to the dataset is increased. To do this, an exponentially 
increasing weighting was explored, as is shown in table 5.2. This involved 
systematically increasing the weighting of the spectral construct added to the 
dataset and examining how the explained variance changes as a result.  
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Table 5.2: weightings used to multiply the spectral constructs of figure 5.2 for the 
determination of the optimum magnitude for seeded PCA. 
 
5.4 Results  
5.4.1. PCA Dataset 1  
Figure 5.3 shows the scatter plot and loadings for PC 1, 2 and 3 following a 
standard PCA of the simplified dataset consisting of the control and simulated 
spectra based on the maximal MTT value, Dataset 1, shown in table 5.1. PC 1, 
PC 2 and PC3 describe the majority variance in the dataset, PC 1, 2 and 3 
accounting for 37.98%, 24.36% and 6.58% of the explained variance, 
respectively. No discernible separation of the control and MTT dataset is 
represented by the scatter plot in figure 5.3A, and this is reflected by the loadings 
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shown in figure 5.4A and B. However, marginal partition of the data is 
demonstrated in figure 5.3B and C, although. no separation between control and 
maximal MTT data is demonstrated. This is due to the inability of PCA to extract 
out the ‘pure’ spectral features introduced in the data, which are not evident in the 
loadings of any of the first 3 PCs (Figure 5.4). 
This poses a problem, as it is not possible to show with standard PCA a 
separation based on the introduction of a known spectral perturbation, or extract 
information concerning that perturbation, as the intrinsic spectral variability is 
larger than that of the systematic variability introduced. To address this, a seeded 
PCA (SePCA) methodology was developed, which allows for a ‘pure’ spectral 
loading, in this case the MTT spectral perturbation, to be extracted with the 
maximal variance described by the desired changes.    
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Figure 5.3. PCA on a dataset consisting of the control and max MTT, dataset 1 
(A) scatter plot of PC1 vs. PC2 (B) scatter plot of PC1 vs. PC3 (C) scatter plot of 
PC2 vs. PC3. PC1, 2 and 3 account for 37.98%, 24.36% and 6.58% of the 
variance in the dataset, respectively.  
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Figure 5.4. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for 
standard PCA on dataset 1. With PC 1, 2 and 3 accounting for 37.98%, 24.36% 
and 6.58% of the variance respectively.  
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5.4.2. Seeded optimisation  
Seeding of the dataset was performed as described in Section 5.3.3. Seeded PCA. 
To optimise for seeding, the variance explained by PC1 and PC2 as the seeded 
weighting is increased according to table 5.2 is examined. The optimisation of 
the weight for seeding is shown in figure 5.5A and B, showing the increase in 
variance explained by the MTT seeded loading, and decreased variance explained 
by the intrinsic spectral variance. “Whereas at 0 weighting, PC1 is dominated by 
the intrinsic variance, at a seeding of 102, PC1 begins to show contributions of 
MTT, while at a loading of 103, it is almost completely dominated by features of 
Construct 2 and completely dominated by Construct 2 at 104 .Therefore, based on 
this plot, the optimal weight to seed for this dataset is ~104 with 99.99% of the 
variance explained by the first PC and an almost negligible 0.01% described by 
the inherent dataset variability. 
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Figure 5.5: Calculation of the variance explained after successive rounds of PCA 
with increasing spectral construct weighting according to table 2. (A) % variance 
explained by the PC loading addition (B) % variance explained by the inherent 
dataset variability between control spectra acquired, instrumental error, random 
noise…etc   
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5.4.3. Seeded PCA dataset 1 
Following seeding optimisation i.e. 104 weighted addition of the MTT spectral 
construct (Construct 2), it is possible to show partition of the data based on the 
known perturbations to the dataset. This is shown in Figure 5.6 A for Dataset 1, 
which now consists of the control spectra (25), the control + WMaxMTT spectra 
(25) and WMaxMTTx10
4 (1). Separation between control and MTT is clearly 
demonstrated. The loadings of PC1, 2 and 3 are shown in figure 5.7 A, B and C 
and account for 99.99%, 0.000059% and 0.000038% of the variance respectively. 
The loading of PC1 faithfully reproduces the MTT spectral construct of Figure 
5.2, the known spectral perturbation added to the dataset. The inherent variability 
of the dataset is now represented by PC2 and 3, and no partition of the data is 
evident along these axis. This demonstrates, in a simplified simulated dataset, the 
enhancement seeded PCA can achieve over the standard implementation of PCA. 
In real experimental data, however, the spectral variations are likely to be more 
complex, as for example in the study of Nawaz et al., in which the spectral 
variations as a result of a chemotherapeutic agent represented both the direct 
chemical effect of the drug as well as the subsequent cellular responses. 
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Figure 5.6. PCA on a dataset consisting of the control and max MTT, dataset 1 
(A) scatter plot of PC1 vs. PC2 (B) scatter plot of PC1 vs. PC3 (C) scatter plot of 
PC2 vs. PC3. PC1, 2 and 3 account for 99.99%, 0.000059% and 0.000038% of 
the variance in the dataset, respectively.  
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Figure 5.7. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for Seeded 
PCA on dataset 1. With PC 1, 2 and 3 accounting for 99.99%, 0.000059% and 
0.000038% of the variance respectively. 
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5.4.4. PCA Dataset 2 
As shown in Figure 5.8, PCA of dataset 2 results in partial differentiation 
according to PC1 and PC2, which account for 93.94%, 2.22% and 1.54% of 
variance in the dataset. PC1 differentiates the spectra perturbed by WMaxConc 
from those of control and perturbed by WMaxMTT. Spectral features pertaining to 
Construct 1 are present in the 1st principal component as shown in figure 5.9A.  
Similar to the case of dataset 1, however, the spectral features of the MTT 
spectral construct introduced into the data are not shown in the first three PC’s. 
Therefore, no separation between control and max MTT is shown in figure 5.8 A-
C. Thus, while conventional PCA can extract the spectral features associated with 
the chemical interaction of the chemotherapeutic agent with the cell, it is not 
sensitive to the weaker changes associated with the subsequent changes to the cell 
metabolism, based on this simulated example.  
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Figure 5.8. PCA of Dataset 2 (A) scatter plot of PC1 vs. PC2 (B) scatter plot 
showing PC1 vs PC3 (C) scatter plot showing PC2 vs. PC3. The variances 
describe by PC 1, 2 and 3 are 93.94%, 2.22% and 1.54% respectively for 
standard PCA. The loadings corresponding to the scatter plots are shown in 
figure 5.9. 
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Figure 5.9. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for Seeded 
PCA on dataset 1. With PC 1, 2 and 3 accounting for 93.94%, 2.22% and 1.54% 
of the variance respectively. 
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5.4.5. Seeded PCA Dataset 2 
In the case where a spectral profile of a minority variant is known, as in the case 
of the MTT construct added to the control data, SePCA can be employed, as 
demonstrated in figure 5.6. To further illustrate the concept for two independent 
variations, a single spectrum of Construct 2, multiplied by a factor of 104 was 
introduced into Dataset 2, as an additional, independent spectrum. The optimised 
value of 104 was chosen as it allows for the majority of the spectral variance to 
be described by the first PC (figure 5.5). Thus, Dataset 2 now consists of the 
control spectra (25), the control + WMaxMTT spectra (25), the control + WMaxConc 
spectra (25), and OSWxC (1), where OSW is the optimised weighting for the 
addition of the spectral construct. 
As shown in figure 5.10, this allows for almost complete separation of 
each spectral group, control, (Control + WMaxMTT) and (Control + WMaxConc ) 
in Dataset 2. The majority of the variance is described by the first PC; 99.99%, 
PC2 and PC3 accounting for 0.003% and 0.000079% variance respectively, at 
this seeded weighting. As a consequence of seeding for the MTT spectral 
changes, partition of the data is now observed between Control and (Control + 
WMaxMTT), according to PC1 (Figure 5.11 A), the loading of which is dominated 
by the MTT construct of Figure 5.2B, as shown in Figure 5.11A. PC2 is 
dominated by the loadings of the spectral features of Construct 1, which shows 
separation along PC2, which differentiates Control and (Control + WMaxMTT) 
from (Control + WMaxConc). No separation is evident according to PC3, the 
loading describing background noise.  
 135 
 
Figure 5.10. Seeded PCA of Dataset 2 (A) scatter plot of PC1 vs. PC2 (B) scatter 
plot showing PC1 vs PC3 (C) scatter plot showing PC2 vs. PC3. The variances 
described by PC 1, 2 and 3 are respectively 99.997%, 0.0033% and 0.000079% 
for seeded PCA. 
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Figure 5.11. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for 
Seeded PCA on dataset 1. With PC 1, 2 and 3 accounting for 99.997%, 0.0033% 
and 0.000079% of the variance respectively. 
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5.4.6. PCA Dataset 3 
Standard PCA of dataset 3 is shown in figure 5.12. This dataset consists of 
systematic changes in both MTT and concentration introduced simultaneously, 
according to table 5.1. As per previous examples in dataset 1 and 2, construct 2, 
the MTT experimental changes are not evident in the first three principal 
component loadings, with the respective variances of 90.99% 7.87%, 0.42% for 
PC 1, 2 and 3. However, the concentration spectral construct is dominant in figure 
5.10 B and is primarily responsible for the separation shown along the PC 2 axis, 
figure 5.9C. Separation is also shown with the first principal component although 
the introduced spectral features of the constructs are not apparent in PC 1, figure 
5.13A-C. 
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Figure 5.12. PCA of Dataset 3 (A) scatter plot of PC1 vs. PC2 (B) scatter plot 
showing PC1 vs PC3 (C) scatter plot showing PC2 vs. PC3. The variances 
described by PC 1, 2 and 3 are respectively 87.82%, 4.51% and 3.13% for PCA. 
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Figure 5.13. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for PCA 
on dataset 3. With PC 1, 2 and 3 accounting for 87.82%, 4.51% and 3.13% of the  
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5.4.7. Seeded PCA dataset 3 
Seeding the algorithm for Construct 2 allows for both the MTT and Concentration 
(Construct 1) to be extracted in the first 2 principal components, as shown in 
figure 5.15 A-C. PC 1 and 2 are responsible for 87.82% and 4.51% of the variance 
in the data, respectively (figure 5.14 A). PC 3 does not result in any differentiation 
of the data. Notably, the differentiation of the data for both MTT and Conc 
variables is continuous, although the degree of separation of each weighting is 
small, in both cases. As a way of increasing the potential for separation, 1st and 
2nd derivative transformations of the data was performed.   
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Figure 5.14. Seeded PCA on dataset 3 (A) scatter plot of PC1 vs. PC2 (B) scatter 
plot showing PC1 vs PC3 (C) scatter plot showing PC2 vs. PC3. The variances 
described by PC 1, 2 and 3 are respectively   99.99%, 0.004% and 0.0002% for 
seeded PCA. 
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Figure 5.15. Loadings of PCA of Dataset 3 corresponding to (A) PC1, (B) PC2 
and (C) PC3. The variances described by PC 1, 2 and 3 are respectively   99.99%, 
0.004% and 0.0002% for seeded PCA. 
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5.4.8. Seeded PCA on 1st derivative spectra  
Further improvements are shown for SePCA on 1st derivative spectra from dataset 
3 in figure 5.16 A – C, a more evident systematic partition of the data being 
produced according to PC1 and PC2, but not PC3, with respective variances of 
99.99%, 0.0079% and 0.0001%. The loading corresponding to the 1st derivative 
of Construct 2 is dominant in PC1, which is reflective of the MTT related spectral 
changes which have been introduced, while PC2 is dominated by the 1st derivative 
of Construct 1, representative of the Concentration spectra changes introduced 
(figure 5.17A-C). For standard PCA derivatisation resulted in no separation for 
dataset 1, and, while for dataset 2 improvements in partition of the data according 
to variations in Concentration were evident, no features of the MTT construct 
were extracted. 
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Figure 5.16. Seeded PCA on 1st derivative spectra from dataset 3 (A) scatter plot 
of PC1 vs.PC2 (B) scatter plot showing PC1 vs PC3 (C) scatter plot showing PC2 
vs. PC3. The variances described by PC 1, 2 and 3 are respectively 99.99%, 
0.0079% and 0.0001% for seeded PCA. 
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Figure 5.17. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for PCA 
on dataset 3. With PC 1, 2 and 3 accounting for 99.99%, 0.0079% and 0.0001% 
of the variance respectively. 
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5.4.9 Seeded PCA on 2nd derivative spectra from Dataset 3 
Considering the improvements in separation achieved following first 
derivatization of Dataset 3, it was subjected to second derivatization, to explore 
whether this resulted in a further improvement in the separation of the spectral 
data. For standard PCA this resulted in no separation for dataset 1, and, while for 
dataset 2 improvements in partition of the data according to variations in 
Concentration were evident, no features of the MTT construct were extracted.     
Figure 5.18 shows the results following seeding of second derivative of 
Dataset 3 with the MTT spectral construct, in the same manner as previous 
analysis. An increased in partition of the data along both PC1 and PC2 is evident 
and both loadings show pure second derivative loadings, from construct 1 and 2 
respectively, figure 5.19 A and B. This enhancement shows the benefits of using 
second derivative spectra and extracting the correct trend from the spectral data.  
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Figure 5.18. Seeded PCA on 2nd derivative spectra from dataset 3 (A) scatter plot 
of PC1 vs. PC2 (B) scatter plot showing PC1 vs PC3 (C) scatter plot showing 
PC2 vs. PC3. The variances described by PC 1, 2 and 3 are 99.99%, 0.0087% 
and 0.000014% for seeded PCA. 
 148 
 
Figure 5.19. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for 
seeded PCA on 2nd derivative spectra from dataset 3. With PC 1, 2 and 3 
accounting for 99.99%, 0.0079% and 0.0001% of the variance respectively. 
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5.5 Discussion 
Validation of multivariate statistical protocols used in vibrational spectroscopy is 
essential to ensure that the spectral analysis is reliable and accurate for 
standardised and routine usage. In the development of novel in-vitro screening 
tools for both nano and pharmacological screening, it is imperative that sample 
preparation protocols, instrumental reliability and multivariate routines are as 
reliable and accurate as possible, to ensure a smooth transition from lab bench to 
clinical and company settings. 
Focusing on the multivariate statistical analysis, previously published 
work by Bonnier and Byrne, 201227, aimed to elucidate the use and 
interpretability of PCA in vibrational spectral applications, using both real and 
simulated data. Similarly, validation and development of the RMie-EMSC 
algorithm was done using simulated and real data in the work of Bassan et al 
201031. These selected examples show the applicability of simulations in 
validation of multivariate analysis as well as spectral prepossessing in a 
biomedical vibrational spectroscopic context.  
The application of PLSR to independently extract information concerning 
the direct chemical interaction of chemotherapeutic agents with cells (Construct 
1), and the subsequent physiological response of the cells using Raman 
spectroscopy in parallel with conventional in-vitro cytotoxicity assays (Construct 
2) was validated using a similar set of simulated spectral datasets by Keating et 
al, 201525. The current work explores the applicability of PCA to the same 
simulated spectral dataset, and its ability to extract the systematic and 
continuously variable spectral perturbations introduced. Limitations of PCA of 
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the data was shown in figure 5.3 A, whereby the algorithm was unable to extract 
the desired spectral features from the dataset, as the magnitude of the perturbation 
was less than the intrinsic variability of the cellular data.  A successful partition 
of the data is shown to be possible when the algorithm is seeded with the known 
spectral variation, as demonstrated in figure 5.5 A and B. In Dataset 3, which is 
continuously perturbed by the addition of weighted contributions of the two 
spectral constructs, seeding the dataset with the minority perturbation enables the 
continuous differentiation of the data, and extraction of both independent spectral 
perturbations. Further improvements in separation are shown using 1st and 2nd 
derivative spectral data for the seeded datasets such that, in the case of the SePCA 
of Dataset 3, the PCA scatter plot shown in figure 5.20A reproduces somewhat 
the experimental dose dependent toxicity study of Nawaz et al, 2010. This has 
implications for in-vitro spectral screening platforms as it shows that the correct 
trend in simulation can be extracted for the data once the correct features are 
described to the algorithm i.e. a seeded approach.  This is a positive step towards 
a multivariate dose response curve. 
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Figure 5.20. Seeded PCA on 2nd derivative spectra from dataset 3 (A) scatter 
plot of PC2 vs. log PC1 (B) loading for PC1 (C) loading for PC2. The variances 
described by PC 1 and 2 are 99.99% and 0.0087% respectively for seeded PCA. 
A constant of 0.05 Arb. Units has been added to PC 2, to allow for log scaling of 
the data. 
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The improvements shown have possible ramifications for both diagnostics 
and in-vitro screening. Notably, however, in comparison to the PLSR approach 
of Keating et al, 2015, the method is supervised, in the context that it requires 
some prior knowledge of the spectral changes in the data set. In terms of Construct 
1, this could be facilitated by a library of spectral signatures of, for example, DNA 
major and minor groove binders and intercalators, allowing a rapid screening of 
mechanisms of action of novel chemotherapeutic agents. In a similar fashion, 
spectral signatures could be established to represent Adverse Outcome Pathways 
(AOPs), an approach to representation of toxicology recently endorsed by the 
OECD32. In this approach, while the chemical binding of the agent to the receptors 
represents the Molecular Initiator Event (MIE), cascade of events leading to, for 
example apoptosis or necrosis constitute the AOP, which could be represented by 
distinct spectral signatures.  
For diagnostic applications such as classification e.g. using support vector 
machines (SVM) or linear discriminant analysis (LDA), in which PCA 
coefficients are input to the algorithms, seeding in combination with 1st and 2nd 
derivative spectra may provide improvements in dividing the data for training and 
thus, improvements in the diagnostic classification accuracy if the correct variable 
features can be identified across the patient data.         
The nature of the continuously varying spectral changes is also relevant 
for the interpretation of experimental changes. In this instance (Dataset 3), the 
changes are continuous and linearly increasing across the entire dataset. However, 
in experimental data, the changes may not be present in a continuous or linear 
fashion, or across the entire sampled range. If, as in many instances, the loadings 
contain an ensemble of spectral features, multiple trends may be responsible for 
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the pattern of separation in the data. By seeding with the correct peaks the pattern 
of partitioning in the data can be more accurately identified and adjusted based 
on the correct spectral changes in the data.   
5.6 Conclusions  
This study demonstrates an analytical methodology, seeded PCA, which increases 
the potential of the PCA algorithm to separate spectrally distinct data, particularly 
in the case where continuous but minor variations are present over a dataset range. 
The use of 1st and 2nd derivatisation of the dataset is demonstrated to further 
enhance the differentiation potential of the algorithm. This has important 
ramifications for improving separation of spectra, with a particular emphasis on 
biomedical spectroscopy, be that in spectral diagnostics i.e. classification 
protocols and/or in-vitro screening of drugs and nano-materials. The study also 
demonstrates the benefits of analysis of simulated datasets in the development 
and validation of novel multivariate analysis algorithms.  
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Chapter 6: Spectral Cross Correlation as a Supervised 
Approach for the Analysis of Complex Raman Datasets: 
The Case of Nanoparticles in Biological Cells  
 
The following is a journal publication in which generation of simulated datasets, 
data pre-processing, writing of the paper, data analysis and development of cross 
correlation as a data mining tool in Raman spectroscopy were carried out by Mark 
E. Keating. Hugh J. Byrne, as supervisor, was primarily responsible for editing 
and refining of the text as well as guidance with the development of the analytical 
technique. Sample preparation and data acquisition were carried out as described 
elsewhere in a paper by Dorney et al1. Franck Bonnier was involved with data 
acquisition and guidance with cross correlation. The format is that of the journal 
publication, but section and figure numbers have been adapted to the format of 
this thesis. 
 
Keating ME, Bonnier F, Byrne HJ. Spectral cross-correlation as a supervised 
approach for the analysis of complex Raman datasets: the case of nanoparticles 
in biological cells. Analyst. 2012 Dec 21;137(24):5792-802. doi: 
10.1039/c2an36169h. 
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6.1 Abstract 
Spectral Cross-correlation is introduced as a methodology to identify the presence 
and subcellular distribution of nanoparticles in cells. Raman microscopy is 
employed to spectroscopically image biological cells previously exposed to 
polystyrene nanoparticles, as a model for the study of nano-bio interactions. The 
limitations of previously deployed strategies of K-means clustering analysis and 
principal component analysis are discussed and a novel methodology of Spectral 
Cross Correlation Analysis is introduced and compared with the performance of 
Classical Least Squares Analysis, in both unsupervised and supervised modes. 
The previous study demonstrated the feasibility of using Raman spectroscopy to 
map cells and identify polystyrene nanoparticles in a lipid rich environment, 
which is suggestive of the membrane rich endoplasmic reticulum. However, short 
comings in identification of all nanoparticle signatures in the cell using K-means 
clustering are apparent, as highlighted by principal component analysis of the 
identified clusters which demonstrates that K-means clustering does not identify 
all regions where spectral signatures of the nanoparticles are evident. Thus, two 
more sophisticated analytical approaches to the extraction of the nanoparticle 
signatures from the Raman spectral data sets, namely classical least squares 
analysis and cross correlation analysis, were employed and are demonstrated to 
improve the identification of spectroscopic signatures characteristic of 
polystyrene nanoparticles in a cellular environment. Additionally, to investigate 
the local biochemical environment in which the nanoparticles are trafficked, a 
pure spectrum of 3-sn-phosphatidyl ethanolamine was cross correlated against the 
Raman data set, further suggesting the particles are indeed localized in a lipid rich 
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environment. Furthermore, to demonstrate the robustness and versatility of the 
analysis method, a spectrum of pure RNA was used to demonstrate that a 
differentiation could be made between DNA of the nucleus and RNA of the 
nucleolus using the supervised spectral cross-correlation technique.     
6.2 Introduction  
Nanotechnology is set to become the first trillion dollar industry in history, with 
predicted benefits which span a wide range of fields, including applications in site 
specific delivery of drugs in humans, to antimicrobial paint coatings and textile 
finishing, to advances in the electronics industry2–7. However, there are caveats 
associated with deploying these nanotechnologies which must be addressed 
before true realistic applications can be widely accepted and adopted as the norm.  
 It is widely known that nanomaterials, more specifically nanoparticles, possess a 
range of unique characteristics which in some ways dictate their usefulness and 
applicability in fields such as medical science. Properties such as increased 
surface to mass ratio result in an increased reactivity and associated novel optical 
properties result in new possibilities in diagnostic and theranostic imaging and 
delivery8,9, while novel semi-conductor properties are applicable to the 
electronics industry10. However, these properties also potentially have negative 
implications, most importantly in terms of the potential impact of nanoparticle 
exposure on human health and the environment. Nanoparticles have been 
demonstrated to be taken up by cells in-vitro and to elicit a toxic response while 
many reports exist of adverse toxic effects in-vivo11–16. 
One of the challenges facing the nanotoxicology community is the 
detection and monitoring of the interaction mechanisms of nanoparticles in 
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cells17,18. Currently, fluorescent microscopy is the most widely used and 
accessible method to study nanoparticle uptake and trafficking19–24. Necessarily, 
however, it relies on the use of inherently fluorescent or labelled compounds for 
visualization and monitoring of nanoparticles inside cells. Most nanoparticles are 
not intrinsically fluorescent, however, and it has been recently demonstrated that 
fluorescent labels can be labile, and that the observation and distribution of 
intracellular fluorescence following nanoparticle exposure is not necessarily 
representative of the presence or distribution of nanoparticles in the cell25. While 
it is also possible to study the dynamics of nanoparticle trafficking using label 
free optical microscopic techniques such as dark field and differential interference 
contrast (DIC) microscopy, the techniques are mainly applicable to metal 
particles such as gold and silver26 Transmission electron microscopy (TEM) 
provides an additional method by which nanoparticles can be visualised in a 
cellular environment27–29. The high lateral resolution obtainable with TEM 
renders it an ideal method for visualising sub cellular organelles and uptake and 
interaction of nanoparticles. However, significant sample processing (fixing and 
ultramicrotoming) is required and only particles with sufficient electronic contrast 
to the cellular environment can be visualised29,30  
Thus, a label-free technique is required which can ideally unambiguously 
identify the presence of the nanoparticles in the cells, their sub-cellular location, 
and their overall effect on the cellular metabolism. Raman spectroscopy is one 
such method which may provide an alternate to traditional approaches for 
studying the nanoparticle-biological interface. The technique provides not only a 
label free method to visualize how the nanoparticle behaves in a biological 
environment, but offers the potential to identify the local environment and 
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simultaneously analyse the associated metabolic changes. To do this, one must 
combine Raman spectroscopy with analytical data mining approaches to extract 
the signatures associated with the nanoparticles but also to probe the environment 
the particles are localized in, and to correlate the exposure and subcellular 
interaction mechanisms with the metabolic changes.   
 Previous studies have indicated the potential of Raman as a label free 
method for studying biological processes. Examples include novel approaches for 
cervical cancer diagnostics31, to investigating the effects following exposure to 
human papilloma virus (HPV) infection32, the effects of chemotherapeutic 
anticancer agents in cells33,34, live cell analysis35,36and the toxic responses to 
single walled carbon nano-tubes (SWCNT), to name but a few37.     
Surface enhanced Raman scattering (SERS) is also a potential method to 
study the intracellular dynamics of nanoparticle trafficking and 
compartmentalisation38,39. However, only certain types of nanoparticle, such as 
gold and silver particles and nanoaggregates have the potential to generate SERS 
spectra, thus limiting the technique to the study of only a certain type of 
nanoparticles. Additionally the surface enhancement process and molecular 
specificity of the technique are not fully understood, which may lead to ambiguity 
in the understanding of cellular trafficking.  
A more recent study indicated the ability of Raman spectroscopy to detect 
the presence of intracellular polystyrene nanoparticles1. Polystyrene was chosen 
as a model nanoparticle for the study as it is commercially available and regularly 
employed as a standard in nanotoxicology (particularly as a positive control in its 
aminated form). Furthermore, the conjugated styrene ring makes it a relatively 
strong Raman scatterer. However, while the identification is somewhat straight 
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forward, the presence of overlapping peaks in both the polystyrene and cellular 
spectra (e.g. both cellular and polystyrene spectra exhibit a strong symmetric ring 
breathing peak at ~1004cm-1) presents a challenging system with which to 
validate the effectivity of the experimental and data analysis techniques. K-means 
clustering analysis (KMCA) analysis was used to differentiate regions of the cell 
as well as to identify and localise the nanoparticles. Analysis of the local cellular 
environment of the detected nanoparticles was performed via a comparison 
between loadings obtained from principal component analysis (PCA) and pure 
spectra of lipids and polystyrene nanoparticles. However, when the data was 
analyzed using PCA, it was noted that the clusters detected using KMCA failed 
to identify all regions which contained the spectral fingerprint corresponding to 
polystyrene in a biological environment. Furthermore, the average spectra of the 
cluster identified by KMCA, while containing features clearly characteristic of 
polystyrene, also contained spectral features of the neighbouring cellular 
environment. Analysis of the loading of the principal components provided a 
clearer differentiation of the nanoparticle contributions from the local cellular 
environment, but neither unsupervised technique provided an unambiguous 
localisation of the target species39. 
Other multivariate analytical approaches have also been applied in the 
field of Raman microspectroscopy of cells. In addition to KMCA, other clustering 
methods such as Fuzzy C means clustering (FCM) and hierarchal cluster analysis 
(HCA) have been used to separate the cellular Raman data into clusters and 
subsequently reshape the data into images40,41. However, as highlighted by 
Headegaard et al., these approaches have their own limitations. In particular 
boundaries between sub-cellular features can often result in the addition of extra 
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clusters with mixed spectral signatures. This addition can be overcome by 
increasing the number of clusters; however, this in turn can result in added 
complexity to interpretation and inaccuracies in regional separation. Additionally, 
the reproducibility of these methods can also be questioned as the starting point 
for the centroid based KMCA and FCM is subjective40.     
PCA and vertex component analysis (VCA) have also been used to 
separate out distinct regions of the cell. With regards to PCA, separation is based 
on the variances between the spectra in the data set, the majority of the variance 
being described by the first three principal components40. Thus, the score values 
can be used to construct a composite image of the cell in which the biochemical 
contributions of each component are described by the corresponding loadings 
plot. Unlike KMCA and FCM, PCA identifies quite accurately the boundaries 
between each feature. However, the images generated suffer from inferior 
contrast and in some instances interpretation may be difficult as biochemical 
features may be spread across different loadings.   
VCA is another method which has been used for similar analytical 
purposes. In brief, VCA computes a linear combination of supposed pure 
component spectra which are termed endmember spectra. As described in 
Miljkovic et al., the endmember spectra are acquired under the assumption that 
the most extreme data points in the dataset are representative of pure component 
spectra41. However, it has been pointed out that the endmembers generated are 
not truly representative of the pure component they describe in the data set and 
can often contain a mixture of biochemical constituents i.e. DNA and proteins42. 
While this is representative of the true nature of nucleic acids in-situ, it could lead 
to inaccuracies in interpretation.  
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The work presented here demonstrates the potential of a Spectral Cross 
Correlation Analysis (SCCA) for the analysis of Raman spectral datasets. The 
method is applied to the dataset of Dorney et al.1, of polystyrene nanoparticles in 
A549 lung adenocarcinoma cells, and is thus compared with previous analyses by 
KMCA and PCA. The performance of SCCA is also compared to that of classical 
least squares analysis (CLSA), performed both in a supervised and unsupervised 
manner, which allows for a direct comparison between both approaches. SCCA 
utilises the spectrum of the target chemical component and cross correlates the 
spectrum with that of the complete Raman spectral dataset. The quantitative 
performance is demonstrated using simulated datasets and the potential is 
demonstrated by mapping the spatial profile of the polystyrene nanoparticles in 
the cells as well as other biochemical components of the cell, (RNA and lipids).  
6.3 Experimental 
 6.3.1 Sample Preparation for Raman Imaging 
A549 Cells were seeded at a density of 4 x 104 cells onto calcium fluoride (CaF2) 
windows (Crystran Ltd., UK) for confocal Raman imaging. The cells were 
incubated for 24 hrs in Dulbecco’s Modified Eagle’s Medium (DMEM F12), 
supplemented with 10% foetal calf serum (FCS) and 1% L-Glutamine at 37°C, 
5% CO2.  Following cell adherence, 2 mLs of medium containing 1x 10
12 
nanoparticles per mL were added to the cells. The cells and nanoparticles were 
incubated for 24hrs at 37°C and 5% CO2.  Following nanoparticle exposure, the 
cells were washed in warm PBS three times and fixed for 10mins in 10% buffered 
formalin. After fixation, the cells were washed to remove any trace of fixative 
and kept in NaCl solution prior to imaging. 
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Component spectra used in SCCA were generated as described in Bonnier 
and Byrne 201243. For polystyrene nanoparticle spectra, nanoparticle suspension 
was added drop-wise to a CaF2 window and allowed to air dry prior to Raman 
acquisition. RNA from baker’s yeast (saccharomyces cerevisiae) was added to 
water and subsequently deposited on a CaF2 window and allowed to air dry. 3-
sn-phosphatidyl ethanolamine was dispersed in chloroform and deposited on 
CaF2 windows.  
6.3.2 Confocal Raman Spectroscopic Imaging 
Confocal Raman Spectroscopic Imaging was performed using a Horiba Yobin-
Yvon LabRAM HR800 spectrometer with a 785nm, 300mmW diode laser as 
source and a Peltier cooled 16-bit CCD. A 100X, N.A. 1.2, (LUMplanF1, 
Olympus) water immersion objective was used for all cellular measurements. The 
confocal pin hole of the system was set to 100µm, the recommended setting for 
confocal operation, to allow optical sectioning of the sample. A 300 lines per mm 
spectroscopic grating, providing a dispersion of ~1.5cm-1 per pixel, was used and 
the system was pre-calibrated to the spectral line at 520.7cm-1 of silicon. Using 
an automated programmable stage, Raman spectra of the cell were acquired with 
a 0.75µm step size over a 29*39 pixel area which encompassed the nuclear, 
perinuclear and cytoplasmic regions of the cell. 
6.3.3 Data Pre-Processing and Preparation  
In order to prepare the data for analysis, a number of steps were taken to ensure 
the spectra in the map were of a high enough quality to give accurate results. For 
CLSA, all data pre-processing was carried out using Labspec 5 software which 
comes as standard on the Raman instrument. Firstly, a background spectrum 
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which constituted the contribution of the CaF2 substrate and water in the imaging 
medium was subtracted from each spectrum in the mapped data set. Following 
subtraction of the background spectrum, a Savitsky-Golay smoothing filter (5th 
order, 7 points), available on the software, was used to lightly smooth the data. 
The data was then baseline corrected using a nodal point baseline correction using 
the minimum amount of points possible to ensure minimal alteration of the 
acquired data. Normalization was carried out automatically by the software 
during CLSA. 
 Data was prepared in a similar fashion for SCCA. However, the pre-
processing was carried out in Matlab (Mathworks,USA) using previously 
published protocols for data processing1. As outlined above, a background 
spectrum was subtracted from the Raman data set to remove the substrate and 
immersion medium contributions. A Savitsky-Golay smoothing filter (5th order, 
7 points) was applied to the data and a nodal point baseline correction was used 
to baseline the data using a minimum amount of reference points to do so. 
Preparation of component spectra for SCCA was done in the same manner for 
polystyrene, RNA and lipids.    
 
6.3.4 Classical Least Squares Analysis 
CLSA was carried out using Labspec 5 software which comes as standard on the 
Raman spectrometer software. The analysis method is based on a fit of a linear 
combination of reference component spectra to the spectra contained in the raw 
spectral map. This is described by Equation 6.1, for the case where three reference 
component spectra are used. S is the sum of the linear contribution of the 
 167 
reference components (A, B, C), and x, y, z are the respective weightings or scores 
necessary for the weighted sum of the reference component spectra to match the 
raw data.  
 
S = [x*A] +[y*B] + [z*C]  Equation 6.1 
 
Using the software, there are two different ways to obtain the reference 
component spectra. The first way is to obtain a pure spectral reference from a 
compound or compounds which can then be fitted according to Equation 6.1. The 
second method uses a factor analysis algorithm to generate the component 
spectra, the weighted sum of which is compared to the Raman spectral data set. 
Using the latter of the two methods, Zavaleta et al demonstrated the power of the 
technique to quantify quantum dot accumulation in an in-vivo mouse model and 
to separate out the different spectral contributions from complex SERS signals in 
the same data set44. In a similar and different way, both approaches to CLSA are 
explored to extract spectra which contain polystyrene nanoparticles and define 
other biochemical regions such as the RNA and lipid rich environments. The 
relative contributions of the different components are defined by the weighting 
factors (x, y, z….).  
6.3.5 Spectral Cross Correlation Analysis 
For SCCA, reference spectra from polystyrene, phosphatidyl-ethanolamine and 
RNA (Figure 6.1 A) were used to screen the Raman spectral data set. All SCCA 
was carried out using Matlab (Mathworks, USA) using the “crosscorr” function 
available in the signal processing toolbox. Equation 6.2 describes the cross 
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correlation between two data series, where C(x) is the correlation function, S(t) is 
the Raman spectrum in the data set to be tested and A(x+t) is the reference 
spectrum i.e. polystyrene, lipid or RNA. The function integrates the product of 
the two data series (spectra) at each point as they are shifted relative to each other 
along the x axis (wave number). The magnitude of the correlation quantifies the 
relative contribution of the component spectrum at that point in the cell, and an 
exact correlation occurs when the spectra are exactly matched (auto-correlation). 
In this way, it is possible to screen the map or spectra in the map and, based on 
the cross correlation function, cluster different biochemical regions of the cell 
based on the relative contributions of the reference spectrum used.     
   Equation 6.2 
6.3.6 Simulated Data  
Simulated data sets were used to test the robustness and sensitivity of both CLSA 
and SCCA in their ability to detect spectral contributions due to polystyrene, RNA 
and lipid in a biological environment. To generate the simulated data sets, a 
cellular spectrum was used as a template to which varied amounts of component 
spectrum were added. Keeping the cellular spectrum constant, a series of 38 
simulated spectra of ratios 1:1 to 1:10-4, cellular: component Raman spectra for 
polystyrene, RNA and lipid were generated (Figure 6.1A). An example of the 
simulated data set for polystyrene is shown in Figure 6.1B, which shows the 
addition of the first 8 spectral dilutions to the constant cellular spectrum. Using 
these simulated datasets, it was possible to explore how each data mining 
approach performs when testing experimental data and thus facilitate accurate 
interpretation of the data sets.   
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Figure 6.1 (A) Component spectra of nano-polystyrene (dotted line), 3-sn-
phosphatidyl ethanolamine (dashed line) and isolated RNA (solid line), offset for 
clarity. (B) Shows an example of the first eight simulated spectra for polystyrene 
in cells, offset for clarity. Each spectrum consists of a constant cellular spectrum 
with a varied concentration of polystyrene added to it, with decreasing 
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polystyrene concentration from top to bottom. Simulated data sets generated in 
this way were then analysed by CLSA and SCCA. 
   
6.4 Results  
6.4.1 Simulated Data – Unsupervised CLSA 
CLSA can be carried out in two different ways, either by generating spectral 
models using a factor analysis algorithm (unsupervised), or by manually inputting 
the component spectra (supervised). The data in Figure 6.2 shows the results 
using the factor analysis generated models for simulated data sets generated based 
on cellular/polystyrene, RNA and lipid spectra (Figure 6.2  B). In each instance, 
the score recorded form CLSA for each spectrum is plotted against the component 
concentration added to the data set. In all cases, the extracted CLSA scores 
accurately represent the true component ratios over the concentration range, 
represented by the solid line. The results depart from nonlinearity a 
cellular:component ratio of ~1:0.1, after which the CLSA weightings no longer 
accurately reflect the correct component weighting, although the presence of the 
component can still be identified in ratios as low as 1:0.03.  
 
 171 
 
Figure 6.2 CLSA of simulated spectral data sets of nano-polystyrene, RNA and 
lipid. In each graph, the score from the CLSA is plotted against the concentration 
of component spectrum added to a constant cellular spectrum (points on each 
graph). The solid black line represents the ideal response which gives an 
indication of the quantitative nature of the technique.   
6.4.2 Single Cell Data – Unsupervised CLSA  
In order to further test the ability of CLSA to identify intracellular polystyrene 
nanoparticles located inside a single cell Raman map, an initial factor analysis 
algorithm was applied to the data set to generate 7 model spectra to be used in the 
CLSA. These model spectra were then used to compute the scores from the 
Raman data set (Figure 6.3 A). It is then possible to segment the cell into different 
distributions based on specific spectral differences as shown in Figure 6.3 B. The 
spectral profile of each model contribution can be visualized individually 
showing the percentage contribution at each pixel (Figure 6.3 C-F). A more 
detailed look at the model spectra generated and corresponding cellular 
distribution can be seen in Figure 6.3 A-G.  
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 The CLSA map shows a different spatial distribution of each model in the 
Raman spectral data set. Although in all cases, the model spectra show strong 
contributions of the cellular environment, they are differentiated by contributions 
from distinct components. Model 1 (Figure 6.4 A) shows characteristic peaks 
corresponding to those seen in pure polystyrene spectra (see Figure 6.1 A). 
Therefore, the pixel distribution of model 1 is deemed to show the localisation of 
the polystyrene nanoparticles, indicating a perinuclear distribution in the cell, 
consistent with the K-means cluster analysis of Dorney et al1. Other models show 
a different distribution in the cell. Model 6 shows a distribution which visually 
corresponds to the nucleolus of the cell (Figure 6.4 B), whereas model 3 surrounds 
the nucleoli and is identified as the nucleus of the cell (Figure 6.4 E). This shows 
the ability of CLSA to differentiate the biochemical regions of the cell containing 
RNA and DNA. Other models such as model 4 (Figure 6.4 C) and model7 (Figure 
6.4 F) show a distinct distribution surrounding the nucleus, which may correspond 
to perinuclear organelles such as the endoplasmic reticulum or the Golgi 
apparatus which are lipid rich regions of the cell.  
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Figure 6.3.: Clustering of spectra identified by unsupervised CLSA. (A) Spectral 
models generated from the analysis protocol and used to generate the clustered 
map shown in (B). The right panel (C-I) shows the distribution of each model 
created in the map. Of particular note, model 1(C), model 6(D) and model 7(H) 
have strong contributions of the spectra of polystyrene, RNA and lipid 
respectively. The spectra in (A) are colour coded and correspond to images (B – 
F), with the exception of Model 6 which corresponds to the white image in (D). 
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Figure 6.4: A closer look at the generated model spectra created by CLSA (A-G). 
The overlap between pixels corresponds to a percentage contribution from each 
particular model. In some instances a pixel may contain 50% of one model and 
50% of another, which is highlighted somewhat by the intensity of the pixel, 
although this is visually subjective.     
6.4.3 Simulated Data - Supervised CLSA  
Unsupervised CLSA is clearly a powerful technique to analyse the subcellular 
structure and to identify the presence and distribution of nanoparticles. However, 
it should be noted that the technique does not yield pure spectra of the components 
(compare for example Figure 6.4 A with the pure spectrum of polystyrene in 
Figure 6.1 A), and the respective models are mixtures of spectral signatures of the 
components and the background cellular spectrum. A secondary approach to 
CLSA which provides a more supervised approach was therefore also tested. In a 
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similar way, the simulated datasets were used to assess the technique prior to 
testing the real Raman cellular map.  
The simulated data sets generated to test the unsupervised factor analysis 
algorithm model generation approach to CLSA were used again to test the 
supervised approach which uses component spectra of polystyrene, RNA and 
lipid as the model spectra to generate scores for each spectrum in the data set.  In 
the simulated data shown in Figure 6.5., it is observed that it is possible to identify 
a trend similar to that seen in Figure 6.2. for the unsupervised CLSA. For RNA 
and lipid, the trend matches well the predicted response for concentrations as low 
as 1:0.1, whereupon it deviates from linearity, falling to zero at a ratio of~1:0.03. 
However, for polystyrene, although the trends are similar, the results are deviate 
from the predicted response much earlier than the unsupervised CLSA. This 
indicates that the identification of the components using a supervised CLSA 
approach may not be as accurate as the model generation approach shown in 
Figure 6.2. Thus, to test this prediction and for comparison, supervised CLSA 
was carried out on the same cellular data set using polystyrene, RNA and lipid 
spectra as the cellular components used to generate the scores for CLSA.     
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Figure 6.5.  Supervised CLSA of simulated spectral data sets of nano-polystyrene, 
RNA and lipid. In each graph, either the pure spectrum of polystyrene, RNA or 
lipid was used to calculate the CLSA score. This score was then plotted against 
the concentration ratio of pure component spectrum: cellular spectrum used to 
generate the simulated data set.  
6.4.4 Single Cell Data - Supervised CLSA  
In order to compare the different CLSA approaches, the cellular Raman data set 
was screened using three pure component spectra individually, nano-polystyrene, 
RNA and lipid. The aim was to use these spectra to generate the CLSA scores and 
thus identify regions of the cell which correspond to each spectrum, identifying 
different regions of the cell based on their biochemical composition and also 
where the nanoparticles were situated.  
 The spectra and corresponding score maps are shown in Figure 6.6.  A – 
C.  Figure 6.6 A shows a spectrum of polystyrene which was used to screen the 
map and corresponding visual image of the distribution of nano-polystyrene in 
the cell. In the image, it is observed that the polystyrene is present in every 
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spectrum in the cell, albeit in differing amounts based on the pixel intensity at 
each point. This is not consistent with the model generated CLSA above or with 
previously published data which show the polystyrene to be localised in clusters 
surrounding the nucleus1. However, the regions of high intensity most likely 
correspond to the areas which contain the nanoparticles.  
 Similarly this method for assessing the distribution of RNA and lipids in 
the cell does not quite reproduce the results observed above for CLSA using the 
unsupervised factor analysis algorithm. Again, it is observed that the distribution 
of lipid and RNA is throughout the Raman map of the cell, which, while more 
plausible for lipids, does not make biological sense for the RNA. Therefore, again 
it must be concluded that the supervised CLSA approach is prone to error, 
although it is still possible to compare regions of high intensity to the output of 
the unsupervised CLSA images above. An arbitrary threshold can be applied to 
the dataset, as is shown for the three component spectra in the right hand panels 
of Figure 6.6 A-C. Using this method, the spatial distributions of the components 
matches well that of the unsupervised CLSA. However this threshold is 
ambiguous and it is not possible to say from the simulated data at what value an 
accurate representation of the biochemical distribution in the cell is achieved.     
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Figure 6.6: Supervised CLSA using component spectra of polystyrene (A), RNA 
(B) and (C) 3-sn-phosphatidyl ethanolamine. The spectrum of each pure 
component is shown on the left of the graph, with the corresponding to non-
thresholded data shown in the middle and arbitrarily thresholded data shown on 
the right.   
6.4.5 Simulated data –Spectral Cross Correlation Analysis 
The observations in Figure 6 that supervised CLSA contained a high level of error 
in the Raman images prompted a search for an alternate supervised approach to 
screening Raman data sets which could be used to unambiguously identify 
regions of the cell which correspond to the pure component spectrum of interest 
chosen, be that polystyrene, RNA, lipid or any other spectral signature which may 
be of interest. A novel technique was thus investigated for the analysis of Raman 
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maps, which uses cross correlation as a method to investigate the presence or 
absence of a component in a complex Raman data set in a supervised manner. 
Thus, SCCA was used to screen the same simulated and real data sets for the 
presence of polystyrene, RNA and lipid for comparison which both methods of 
CLSA.       
Spectral cross correlation analysis (SCCA) was initially investigated 
using the same simulated data sets that were used to investigate both CLSA 
approaches. Similar to the supervised CLSA approach, pure component spectra 
were used to screen each data set for the presence of each in their respective 
simulated data set. Figure 6.7 compares the results of the simulated SCCA for 
each of the different components polystyrene, lipid and RNA. In all cases, a 
correlation of the SCCA co-efficient and the true concentration ratios is observed, 
but to varying degrees of accuracy. 
For polystyrene, a minimum correlation coefficient value of ~ 0.3 is 
reached at a concentration ratio of cellular: polystyrene spectrum of ~ 1:0.1. This 
indicates that at this concentration ratio, the presence of the polystyrene spectral 
fingerprint cannot be distinguished from the cellular spectrum. Thus, for the 
practical implications of screening a cell for polystyrene nanoparticles, 
correlation coefficient values at or below 0.3 represent the cellular peaks which 
overlap with characteristic polystyrene peaks and thus values below this are 
deemed not to be nanoparticles. This hypothesis was tested using a blank Raman 
map which contained no polystyrene data in (data not shown) and a value of 
correlation of 0.3125 was determined, which is close to the predicted value in the 
simulated data sets. This indicates the need to threshold cellular data in order to 
identify polystyrene nanoparticles in the cell. 
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 A similar performance was observed for both RNA and lipid simulated 
data sets, where an initial decrease in the correlation coefficient was observed in 
relation to concentration ratio of pure component: cell spectrum. Again a 
minimum baseline correlation coefficient was observed for both RNA and lipid 
simulated SCCA data. Notably, however, this value was different, in both cases 
higher, than that observed for polystyrene, possibly due to an increased overlap 
of Raman bands present in the lipid and RNA spectra with cellular Raman bands 
in comparison to the polystyrene spectrum. In the case of the lipid contribution, 
the correlation with the predicted response is quantitatively poor even at ratios 
above 1:0.1. However, this can possibly be explained by lipid contributions 
already present in the cellular spectrum and/or the relatively broad lipid bands 
present in the lipid spectrum used. 
 The next step was to investigate the performance of SCCA in a real 
Raman data set of the cell. Thus the previous map was screened in a supervised 
manner to investigate if nano-polystyrene could be identified in the Raman map.  
Additionally, the lipid spectrum was used to see if the local cell environment 
could be investigated. Also, as used in the above supervised CLSA, RNA was 
used to see if a differentiation could be made between the nucleus and nucleolus.   
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Figure 6.7. SCCA carried out on simulated data sets containing added 
polystyrene, RNA and lipid component spectra. In each instance, a pure 
component spectrum of polystyrene, RNA and lipid was cross correlated against 
each data set to investigate the performance of the technique. The solid line shows 
the idealised response.  
6.4.6 Single Cell Data –SCCA 
SCCA was used to screen the Raman data set for the presence of polystyrene, 
RNA and lipid distributions. The spectra and correlation maps are shown in 
Figure 6.8. In figure 6.8 A, the spectrum of polystyrene is shown in red and the 
corresponding correlation map is shown adjacent for both thresholded (right) and 
non-thresholded (left) datasets. This map shows the distribution of polystyrene 
nanoparticles in the Raman map. Importantly, the threshold which was predicted 
from the simulated data, or more simply from a cross-correlation of the 
component spectrum with the raw average cellular spectrum, was applied to the 
data set and returned a map which corresponded to the previously observed 
Raman image from the unsupervised CLSA (Fig 6.3 A). Notably, however, the 
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spectrum is the pure spectrum of polystyrene, rather than a cellular/polystyrene 
mixture. This result shows the capability for a supervised approach for the 
unambiguous identification of polystyrene nanoparticles in complex Raman 
spectroscopic data sets. 
 Furthermore, to investigate how SCCA can be used to probe the local 
cellular environment, the lipid spectrum was used to screen the data set (Fig 6.8 
B). Again applying a threshold to the data set it is possible to identify regions of 
the cell which contain a high density of lipids using a supervised approach to 
Raman analysis. Thus it is possible to investigate the local cell environment to 
which the nanoparticles are trafficked after 24hrs. This is consistent with the 
previous K-means cluster analysis1 which suggests that indeed the nanoparticles 
are located in a highly lipid rich environment.  
 As an additional demonstration of the potential of SCCA, a pure RNA 
spectrum was cross correlated against the data set to see if it was possible to 
differentiate spectra which corresponded to the nucleolus of the cell and thus 
differentiate between DNA and RNA rich regions of the cell. Figure 4.5.7.1. C 
shows that it is possible to identify the nucleolus of the cell using cross correlation 
analysis. It was also observed that a high correlation coefficient was present in 
regions outside the nucleus. This could possibly correspond to cytoplasmic 
ribosomal RNA (rRNA) or cytoplasmic messenger RNA (mRNA). Thus a novel 
approach for extracting complex spectral information from Raman data sets is 
demonstrated in SCCA.    
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Figure 6.8: SCCA analysis using component spectra of polystyrene (A), 3-sn-
phosphatidyl ethanolamine (B) and RNA (C). The spectrum of each pure 
component is shown on the left of the figure and the correlation maps for non-
thresholded shown in the middle and thresholded on the right.   
6.5 Discussion  
Raman spectroscopy is a powerful tool for the investigation of biological samples. 
Previous studies have shown the capability of the technique to investigate sub 
cellular structures and processes which provide Raman images comparable to 
images observed using wide-field and confocal fluorescent microscopy1,36,45–47. 
Notably, however, Raman spectroscopy is a label free method which provides a 
visualization of the biochemical make up of a cell without costly and time 
consuming processing with reagents, and when combined with appropriate 
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analysis methods can provide a wealth of information pertaining to biological 
processes in the cell. The aim of this paper was thus to investigate two analytical 
approaches both in an unsupervised and supervised approach and assess their 
ability to identify polystyrene nanoparticles and biochemical distributions in a 
single cell Raman map.  
Unsupervised CLS analysis is demonstrated to be capable of identifying 
the presence of nanoparticles in regions of the cell. However, while this method 
is valuable for identifying distributions in the cell, the model spectra generated in 
this manner must be further analysed to extract any real biochemical information. 
Therefore, while the analysis of the simulated dataset in figure 6.2. indicates that 
the unsupervised model has a higher accuracy, the model spectra yielded by the 
unsupervised CLS analysis do not directly compare to the pure component spectra 
shown in Figure 6.1 and therefore cannot be used to unambiguously identify the 
contributing components.  
 In contrast, employing supervised approaches to the analysis of Raman 
data sets allows for the spectral array to be screened directly with the nanoparticle 
or pure biochemical component spectrum of interest. Analysis in this way enables 
a direct screening of the cellular distribution of a particular component while 
simultaneously probing the chemical or biochemical environment of the 
particular location in the cell. CLSA and SCCA are both used in a supervised 
approach for analysing Raman cellular data sets (Figure 6.6 and Figure 6.6). 
However, unthresholded, both show a degree of error for all three components 
tested (nano-polystyrene, RNA and Lipids).  To correct for this, a threshold can 
be applied to both CLSA and SCCA. Importantly, this threshold should not be 
applied in an arbitrary manner, as this facilitates a loss of information from the 
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dataset. While thresholding for supervised CLSA is arbitrary and subjective, the 
simulated datasets generated for SCCA provided a good estimation of where this 
thresholding should take place and in combination with cellular data containing 
no nanoparticles it was possible to accurately reveal where the nanoparticles were 
located in the cell. It should be noted that the thresholding level appears to be 
dependent on the spectral profile of the individual component, as it is dependent 
on the degree of similarity of the spectrum of the target component with that of 
the environment. Incorrect correction of spectral background may also add to the 
threshold. On the other hand the simulated data for supervised CLSA did not 
provide a threshold value to apply to the dataset and thus was arbitrarily 
thresholded, which is far from ideal to gain any reliable information about the 
dataset. Therefore, SCCA provides a more reliable supervised approach for 
identification of nanoparticles and other biological components when used in 
combination with a threshold generated by simulated datasets.  In addition, 
quantitative information can be extracted from the simulated data sets, with each 
of the three approaches showing some level of quantification based on how well 
the matched the predicted response, with SCCA showing the highest level of 
sensitivity of the three techniques. SCCA is specifically a supervised approach, 
as it is necessary to provide the pure component spectrum. However, it is 
conceivable the technique could be extended to a library of reference spectra 
which could in turn be screened against the data set in an unsupervised manner. 
6.6 Conclusions 
CLSA and SCCA are shown to be two methods capable of identifying 
intracellular polystyrene nanoparticles and also to probe the local biochemical 
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environment the nanoparticles are trafficked to within the cell. CLSA is a 
relatively straight forward method for analysing spectroscopy data sets. However, 
SCCA is demonstrated in the simulated data sets to be a more sensitive approach 
for nanoparticle identification. It is envisaged that both these and other supervised 
methods will provide analytical approaches which can be used not only as 
identification methods for other nanoparticles inside cells and detection of 
resultant biochemical changes, but also to provide alternate analytical approaches 
to the study of other processes such as chemotherapeutic response of cells to 
drugs. Additionally the full quantitative nature of these analytical approaches will 
need to be explored if Raman spectroscopy is to become a routine application in 
the study of nano-bio interactions and beyond.   
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 Chapter 7: Conclusions 
Given the drive for a reduction in the use of animal models for evaluating toxicity, 
screening of drugs and even cosmetics, due to regulatory developments in both 
the EU and US (EU Directive-2010/63/EU and US Public Law 106-545, 2010, 
106th Congress)1–3 generally based on the 3 R’s of Russell and Burch30 to replace, 
reduce and refine the use of animals used for scientific purposes, there is increased 
emphasis on the development of reliable and rapid in-vitro screening 
methodologies. This includes more representative culture models which better 
mimic the in-vivo environment as well as more rapid, cost efficient, high content, 
and ideally label free screening technologies. It is crucial, however, that these 
models and technologies are well validated against established gold standards4,5.  
Raman spectra, in principle, contain high content information about the 
biochemical make-up of the sample, and changes to it, related to pathology or an 
external agent. Raman spectra contain numerous peaks which vary dependently 
and independently of each other. Chapter 2 reviewed some of the current and 
emerging applications of Raman spectroscopy in the field of Nanomedicine, for 
example. Extraction and analysis of the relevant data requires the application of 
multivariate statistical protocols, and validation of such protocols used in 
vibrational spectroscopy, many of the commonly employed modes of which were 
introduced in Chapter 3, is essential to ensure that the spectral analysis is reliable 
and accurate for standardised and routine usage. In the development of novel in-
vitro screening tools for both nano and pharmacological screening, it is therefore 
imperative that sample preparation protocols, instrumental reliability and 
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multivariate routines are robust and reproducible, to ensure a smooth transition 
from laboratory bench to clinical and industrial settings. 
Focusing on the multivariate statistical analysis, previously published 
work by Bonnier and Byrne, 20126, aimed to elucidate the use and interpretability 
of PCA in vibrational spectral applications, using both real and simulated data. 
Similarly, validation and development of the RMie-EMSC algorithm was done 
using simulated and real data in the work of Bassan et al 20107. These selected 
examples show the applicability of simulations in validation of multivariate 
analysis as well as spectral prepossessing in a biomedical vibrational 
spectroscopic context.  
Crucial to the application of Raman spectroscopy in these areas is the use 
of data mining and data analysis, as a way to identify trends in the spectral data, 
which is important as a tool to extract and distil spectral information which may 
not be apparent to the eye.  
For diagnostics, classification of samples is sufficient, and accuracy of 
sensitivities and specificities are important for translational to the clinic. To go 
beyond, and make use of analytical capabilities of Raman spectroscopy, data 
mining is important in the exploration of the potential of the technique for dose 
dependent in-vitro studies and mechanistic responses for both drug and nano- 
toxicological and screening applications. It is also imperative that spectroscopic 
techniques are compared and validated against gold standard assays and 
diagnostic classification protocols to ensure accurate, reliable and robust spectral 
methodologies in these settings.  
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A differentiation should be made between the screening of cell 
populations i.e. point by point cellular acquisition and Raman as a whole cell and 
sub-cellular imaging, technique. Both provide label free analysis, although the 
type of knowledge gained is different; cell population screening provides 
information how a drug or nanomaterial may effect the average cell viability of a 
population 8–10, while as an imaging technique, information is gained about the 
subcellular spatial distribution and mode of action of drugs and nanomaterials11,12.        
Crucially, for real applications and particularly in the instance of drug 
interactions, it is difficult to tell whether these differences are inherently based on 
cell to cell variability or whether they are dependent on the primary action of the 
drug (i.e. the direct chemical effects) or the secondary effects the drug has on the 
cell (i.e. the response of the cell to said drug). 
In Chapter 4, simulated datasets were used to evaluate the capability of 
PLSR to extract known and systematic spectral variation from a control dataset, 
which contained intrinsic experimental variability. The spectral variations 
introduced varied linearly with the applied drug dose and also with the cell 
population response, as measured by a standard cytotoxicity assay. Notably, 
however, the two spectral variations are not completely independent, as the 
viability response is sigmoidal dependent on the applied dose. 
In the case where only a concentration dependent systematic variation in 
the spectra is introduced, the PLSR model provides an accurate predictive 
response tool, the regression co-efficients of which are based on the systematic 
variation which has been introduced to the dataset, linearly dependent on the 
targets. The model shows high sensitivity, and the limits of detection are 
determined only by the intrinsic variability of the experimental method, as 
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determined by the PLSR of the Control spectral dataset. This limit can be 
improved by optimising sample preparation and measurement protocols. In 
principle, such a PLSR model can predict the response of a drug dose in a cell 
population, or determine an unknown drug dose from a measured spectral 
response. 
However, the spectral changes which result from the interaction and 
action of a drug within a cell are manifold, and it is of interest to differentiate the 
spectral signatures of the direct interaction from the subsequent cellular response. 
Notably, this study demonstrates that, although PLSR predictive models based on 
regression of the combined dataset, including all spectral responses, against the 
target of concentration range produce a similarly accurate, linear predictive 
model, the contributing regression co-efficient (RCs) are derived exclusively 
from the introduced concentration dependent variations in ranges where all other 
spectral variations are limited. For example, as shown in Figures 4.8 and 4.9, 
regression over the limited range of C+4 produces a model which is based on RCs 
which include contributions derived from the direct effect of the interaction of the 
drug within the cell (Concentration construct), as well as the resultant cytological 
response (Viability construct). Thus, care should be taken in interpreting the 
spectral features which contribute to such regressions to elucidate the underlying 
mechanisms. 
Nevertheless, in the sub-lethal regions, the direct effects of the drug 
interaction can confidently be investigated employing such a PLSR analysis of 
Raman spectral data, independent of the cytological responses, and these are 
easily discernible above the intrinsic variability of the control. Although this 
seems a trivial conclusion, such rapid, label free analysis could prove invaluable 
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in screening of, for example, the mechanisms and efficacy of drug interactions, 
evaluating drug uptake and receptor binding or nanoparticle uptake and 
trafficking in regions where cytoxicity assays are insensitive. 
The use of a parallel cytotoxic assay, such as MTT, serves as a range 
finding test to establish the IC50, but also provides vital information about the sub-
lethal doses and maximum responses. It also provides a target for regression of 
the data in the regions of toxicity. Thus, the subsequent cytological effects can be 
differentiated from the direct chemical effects of the agent and extracted from the 
overall spectral response in the dose range where the viability is impacted, and 
the cellular response can be independently mapped spectroscopically, as a 
function of dose and time. Notably, the model described in Chapter 4, which 
includes a single spectral construct to represent the cellular response is very 
simplistic, as the response is a cascade of many responses, depending on the 
mechanism of interaction13. Nevertheless, the analysis presented here 
demonstrates that the spectral fingerprints of the direct mechanisms of interaction 
and the subsequent cellular responses can be independently extracted from the 
dose dependent spectral data, and thus, ultimately with improved screening 
sensitivities and speeds, Raman spectroscopy could be employed to monitor in 
quasi real time, in a label free manner, the efficacy and mode of action of, for 
example chemotherapeutic agents and other exogenous agents, laying the basis 
for improved quantitative structure activity relationships to guide drug 
development or chemical regulation strategies.  
This study demonstrates the reliability and also limitations of PLSR as a 
method for predictive modelling and analysis of spectroscopic signatures of 
cellular responses to exogenous agents such as radiation, chemotherapeutic 
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agents or toxins. The spectroscopic profiles at any dose/time point can derive 
from a complex mixture of direct interactions within the cell and a cascade of 
subsequent cellular response. The analysis demonstrates that care should be taken 
in choosing the response range and also highlights the importance of parallel 
cytological assays in guiding the modelling and analysis. Correct choice of range 
can help differentiate between the signatures of direct interactions, which are 
dominant at sub-lethal doses and those of the subsequent cellular response which 
evolve with increasing dose. 
PCA of the same simulated spectral dataset was also investigated for its 
ability to extract the systematic and continuously variable spectral perturbations 
introduced. Limitations of PCA of the data are shown in figure 5.3 A, whereby 
the algorithm was unable to extract the desired spectral features from the dataset, 
as the magnitude of the perturbation was less than the intrinsic variability of the 
cellular data.  A successful partition of the data is shown to be possible when the 
algorithm is seeded with the known spectral variation, as demonstrated in figure 
5.5 A and B. In Dataset 3, which is continuously perturbed by the addition of 
weighted contributions of the two spectral constructs, seeding the dataset with the 
minority perturbation enables the continuous differentiation of the data, and 
extraction of both independent spectral perturbations. Further improvements in 
separation are shown using 1st and 2nd derivative spectral data for the seeded 
datasets such that, in the case of the SePCA of Dataset 3, the PCA scatter plot 
shown in figure 5.20A reproduces to some degree the experimental dose 
dependent toxicity study of Nawaz et al. This has implications for in-vitro spectral 
screening platforms as it shows that the correct trend in simulation can be 
extracted from the data once the correct features are described to the algorithm 
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i.e. a seeded approach. This is a positive step towards a multivariate dose response 
curve. 
The improvements shown have possible ramifications for both diagnostics 
and in-vitro screening. Notably, however, in comparison to the PLSR approach 
of Chapter 5, the method is supervised, in the sense that it requires some prior 
knowledge of the spectral changes in the data set. In terms of Construct 1, this 
could be facilitated by a library of spectral signatures of, for example, DNA major 
and minor groove binders and intercalators, allowing a rapid screening of 
mechanisms of action of novel chemotherapeutic agents. In a similar fashion, 
spectral signatures could be established to represent Adverse Outcome Pathways 
(AOPs), an approach to representation of toxicology recently endorsed by the 
OECD14. In this approach, while the chemical binding of the agent to the receptors 
represents the Molecular Initiator Event (MIE), cascade of events leading to, for 
example apoptosis or necrosis constitute the AOP, which could be represented by 
distinct spectral signatures.  
For diagnostic applications such as classification e.g. using support vector 
machines (SVM) or linear discriminant analysis (LDA), in which PCA 
coefficients are input to the algorithms, seeding in combination with 1st and 2nd 
derivative spectra may provide improvements in dividing the data for training and 
thus, improvements in the diagnostic classification accuracy if the correct variable 
features can be identified across the patient data.         
The nature of the continuously varying spectral changes is also relevant 
for the interpretation of experimental changes. In this instance (Dataset 3), the 
changes are continuous and linearly increasing across the entire dataset. However, 
in experimental data, the changes may not be present in a continuous or linear 
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fashion, or across the entire sampled range. If, as in many instances, the loadings 
contain an ensemble of spectral features, multiple trends may be responsible for 
the pattern of separation in the data. By seeding with the correct peaks the pattern 
of partitioning in the data can be more accurately identified and adjusted based 
on the correct spectral changes in the data.   
This study demonstrates an analytical methodology, seeded PCA, which 
increases the potential of the PCA algorithm to separate spectrally distinct data, 
particularly in the case where continuous but minor variations are present over a 
dataset range. The use of 1st and 2nd derivatisation of the dataset is demonstrated 
to further enhance the differentiation potential of the algorithm. This has 
important ramifications for improving separation of spectra, with a particular 
emphasis on biomedical spectroscopy, be that in spectral diagnostics i.e. 
classification protocols, and/or in-vitro screening of drugs and nano-materials. 
The study also demonstrates the benefits of analysis of simulated datasets in the 
development and validation of novel multivariate analysis algorithms.  
Moving from dose dependent responses in cell populations to analysis of 
cells and cellular processes, Raman spectroscopy may also be deployed as an 
imaging technique with subcellular resolution. Previous studies have shown the 
capability of the technique to investigate sub cellular structures and processes. As 
an optical technique, Raman images are comparable to those produced using 
wide-field and confocal fluorescent microscopy11,15–18. This is demonstrated 
further in chapter 6, in which two analytical approaches, unsupervised and 
supervised where assessed based on their ability to identify polystyrene 
nanoparticles and biochemical distributions in an experimental single cell Raman 
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map. Simulation models were employed to quantitatively compare the relative 
sensitivities of the data mining techniques.  
Unsupervised CLS analysis is demonstrated to be capable of identifying 
the presence of nanoparticles in regions of the cell. However, while this method 
is valuable for identifying distributions in the cell, the spectra generated in this 
manner must be further analysed to extract any real biochemical information. 
Therefore, while the analysis of the simulated dataset in figure 6.2. indicates that 
the unsupervised model has a higher accuracy, the model spectra yielded by the 
unsupervised CLS analysis do not directly compare to the pure component spectra 
shown in Figure 6.1 and therefore cannot be used to unambiguously identify the 
contributing components.  
 In contrast, employing supervised approaches to the analysis of Raman 
data sets allows for the spectral array to be screened directly with the nanoparticle 
or pure biochemical component spectrum of interest. Analysis in this way enables 
a direct screening of the cellular distribution of a particular component while 
simultaneously probing the chemical or biochemical environment of the 
particular location in the cell. CLSA and SCCA are both used in a supervised 
approach for analysing Raman cellular data sets (Figure 6.6 and Figure 6.6). 
However, un-thresholded, both show a degree of error for all three components 
tested (nano-polystyrene, RNA and Lipids). To correct for this, a threshold can 
be applied to both CLSA and SCCA. Importantly, this threshold should not be 
applied in an arbitrary manner, as this facilitates a loss of information from the 
dataset. While thresholding for supervised CLSA is arbitrary and subjective, the 
simulated datasets generated for SCCA provided a good estimation of where this 
thresholding should take place and, in combination with cellular data containing 
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no nanoparticles, it was possible to accurately reveal where the nanoparticles 
were located in the cell. It should be noted that the thresholding level appears to 
be dependent on the spectral profile of the individual component, as it is 
dependent on the degree of similarity of the spectrum of the target component 
with that of the environment. Inappropriate correction of spectral background 
may also add to the threshold. On the other hand, the simulated data for supervised 
CLSA did not provide a threshold value to apply to the dataset and thus was 
arbitrarily thresholded, which is far from ideal to gain any reliable information 
about the dataset. Therefore, SCCA provides a more reliable supervised approach 
for identification of nanoparticles and other biological components when used in 
combination with a threshold generated by simulated datasets. In addition, 
quantitative information can be extracted from the simulated data sets, each of the 
three approaches showing some level of quantification based on how well they 
matched the predicted response, SCCA showing the highest level of sensitivity of 
the three techniques. SCCA is specifically a supervised approach, as it is 
necessary to provide the pure component spectrum. However, it is conceivable 
the technique could be extended to a library of reference spectra which could in 
turn be screened against the data set in an unsupervised manner. 
CLSA and SCCA are shown to be two methods capable of identifying 
intracellular polystyrene nanoparticles and also to probe the local biochemical 
environment the nanoparticles are trafficked to within the cell. CLSA is a 
relatively straight forward method for analysing spectroscopy data sets. However, 
SCCA is demonstrated in the simulated data sets to be a more sensitive approach 
for nanoparticle identification. It is envisaged that both these and other supervised 
methods will provide analytical approaches which can be used not only as 
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identification methods for other nanoparticles inside cells and detection of 
resultant biochemical changes, but also to provide alternate analytical approaches 
to the study of other processes such as chemotherapeutic response of cells to 
drugs.  
Previous work investigating biochemical information, which can been 
gained from using multivariate statistical methods has been explored by Bonnier 
et al19 where PCA and k-means were used to investigate cellular data, while this 
study primarily uses real data to explore the capabilities of these methods, some 
of the work in this thesis uses simulations to probe the usefulness of such methods 
in biomedical spectroscopy.  
While these methods provide approaches for the study of individual cells, 
it is important to note that the exact changes present in the spectra are still 
partially unknown and thus it is difficult to ensure that all spectra are classified 
and group precisely, in an error free manner.  
7.1 Future work 
Future work may involve the design of an advanced cellular simulated model, as 
indicated in figure 7.1. As a demonstration of principle, the generation of a model 
dataset was initially undertaken using K-Means clustering of the nanoparticle 
exposed cellular dataset of Dorney et al11. The purpose here was to generate 6 
clusters in the dataset which corresponded roughly to the different spatial regions 
of the cell i.e. the nucleus, nucleolus, perinuclear regions of the cell, the 
surrounding cytoplasm and an external agent, in this case polystyrene 
nanoparticles. This was achieved by splitting the resulting matrix obtained from 
KMCA into separate regions which correspond to the clusters identified in the 
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analysis. The six matrixes were then converted to binary format by replacing all 
values to a series of ones and zeros. This process allows for the generation of 
template datasets or images. Next, spectra were chosen which, in this initial 
dataset, are pure component spectra of two lipid spectra, phosphatidyl inositol 
and phosphatidyl ethanolamine, DNA, RNA, a spectrum of the background and 
a spectrum of polystyrene nanoparticles.  
These spectra are then used to populate the image templates generated 
using K-means clustering. Thus, if the templates consist of a series of ones and 
zeros, by a process of multiplication only, the regions which contain a one will 
contain a spectrum. Thus it is possible to populate the dataset with any spectrum 
of interest. As stated, in this case the dataset is based on nanoparticle cell 
interaction, so in this initial simplified dataset the examples used consist of pure 
spectral components which are matched to a corresponding regional distribution. 
This is shown in table 7.1   
This outlines a preliminary example of a biochemical spatial simulation 
of the cell based on pure cellular components. While this example is simplistic in 
nature, mixing of the base components in different weightings may lead to a better 
understanding of statistical methods used for Raman cellular imaging. Extending 
this concept of Raman imaging to high content cellular imaging, such a cellular 
simulated model could serve as a template to validate and extend data mining, 
towards a robust analysis protocol.  
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Figure 7.1. Initial template regions showing the known spatial distribution of 
pure component spectra representing the Nucleus (A), Perinuclear 1 (B), 
Cytoplasm (C), Nucleolus (D), Perinuclear 2 (E) and Polystyrene nanoparticles 
(F). This spectral regions correspond to the pure component spectra in table 7.1 
and figure 7.2. 
 
Table 7.1. Pure spectral components and corresponding regional distributions  
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Figure 7.2: Clusters representing the Nucleus (A), Perinuclear 1 (B), Cytoplasm  (C), 
Nucleolus (D), Perinuclear 2 (E) and Polystyrene nanoparticles (F).  
 
Future work may also look to develop the algorithms of sePCA and 
SCCA, this could possibly look at areas such as disease diagnostics, coupling 
these methods with classifier algorithms such as SVM could lead to the 
development of novel approaches, with a high sensitivity and specificity for 
certain disease states. 
 While there are some limitations to this study, only Raman spectroscopy 
is used, possibly incorporation of other spectral techniques such as IR, CARS, 
SRS, might added to the scope of this study, expansion to include real data in the 
evaluations could progress the methods used and see them progress to routine 
usage in data analytics. 
A sound knowledge of the workings of these and other multivariate 
statistical methodologies validated and verified in simulation, may lead to more 
robust and accurate multivariate statistical protocols in the biomedical 
spectroscopy field. Other modalities may also benefit, such as CARS and SRS, 
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as these techniques begin to gain ground and move towards a full spectrum video 
rate imaging technology 20,21. 
Advanced simulations may also be used to identify possible artefacts from 
instrumental error and sample preparations, by the known introduction of these 
changes and their effect downstream at the analytical stage. 
In conclusion advanced simulations have been demonstrated to shed light 
on multivariate statistical methodologies used for in-vitro screening for Raman 
spectroscopy. The knowledge demonstrated in this thesis may aid in the 
understanding and development of real data protocols to ensure accurate, valid 
and correct application of multivariate statistical methods in the future.      
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